

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Cord blood metabolic signatures predictive of childhood overweight and rapid growth

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1799262> since 2021-09-03T13:01:36Z

Published version:

DOI:10.1038/s41366-021-00888-1

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

This is the author's final version of the contribution published as:

Evangelos Handakas, Pekka Keski-Rahkonen, Lida Chatzi, Rossella Alfano, Theano Roumeliotaki, Michelle Plusquin, Léa Maitre, Lorenzo Richiardi, Sonia Brescianini, Augustin Scalbert, Nivonirina Robinot, Tim Nawrot, Franco Sassi, Martine Vrijheid, Paolo Vineis & Oliver Robinson. Cord blood metabolic signatures predictive of childhood overweight and rapid growth. *Int J Obes (Lond)* 2021 Jul 12.
doi: 10.1038/s41366-021-00888-1. Online ahead of print.

The publisher's version is available at:

<http://hdl.handle.net/2318/494617>

When citing, please refer to the published version.**Link to this full text:**

<http://hdl.handle.net/2318/494617>

This full text was downloaded from iris-AperTO: <https://iris.unito.it/>

Cord blood metabolic signatures predictive of childhood overweight and rapid growth

Evangelos Handakas, Pekka Keski-Rahkonen, Lida Chatzi, Rossella Alfano, Theano Roumeliotaki, Michelle Plusquin, Léa Maitre, Lorenzo Richiardi, Sonia Brescianini, Augustin Scalbert, Nivonirina Robinot, Tim Nawrot, Franco Sassi, Martine Vrijheid, Paolo Vineis & Oliver Robinson

Corresponding author: Oliver Robinson

Abstract

Introduction

Metabolomics may identify biological pathways predisposing children to the risk of overweight and obesity. In this study, we have investigated the cord blood metabolic signatures of rapid growth in infancy and overweight in early childhood in four European birth cohorts.

Methods

Untargeted liquid chromatography-mass spectrometry metabolomic profiles were measured in cord blood from 399 newborns from four European cohorts (ENVIRONAGE, Rhea, INMA and Piccolipiu). Rapid growth in the first year of life and overweight in childhood was defined with reference to WHO growth charts. Metabolome-wide association scans for rapid growth and overweight on over 4500 metabolic features were performed using multiple adjusted logistic mixed-effect models and controlling the false discovery rate (FDR) at 5%. In addition, we performed a look-up analysis of 43 pre-annotated metabolites, previously associated with birthweight or rapid growth.

Results

In the Metabolome-Wide Association Study analysis, we identified three and eight metabolites associated with rapid growth and overweight, respectively, after FDR correction. Higher levels of cholestenone, a cholesterol derivative produced by microbial catabolism, were predictive of rapid growth ($p=1.6 \times 10^{-3}$). Lower levels of the branched-chain amino acid (BCAA) valine ($p=8.6 \times 10^{-6}$) were predictive of overweight in childhood. The area under the receiver operator curve for multivariate prediction models including these metabolites and traditional risk factors was 0.77 for rapid growth and 0.82 for overweight, compared with 0.69 and 0.69, respectively, for models using traditional risk factors alone. Among the 43 pre-annotated metabolites, seven and five

metabolites were nominally associated ($P < 0.05$) with rapid growth and overweight, respectively.

The BCAA leucine, remained associated (1.6×10^{-3}) with overweight after FDR correction.

Conclusion

The metabolites identified here may assist in the identification of children at risk of developing obesity and improve understanding of mechanisms involved in postnatal growth. Cholestenone and BCAAs are suggestive of a role of the gut microbiome and nutrient signalling respectively in child growth trajectories.

Introduction

Childhood obesity has become a global epidemic in developed as well as in developing countries [1], with significant long-term consequences on both physical and psychological health, social and economic outcomes [2]. Behavioural dimensions such as diet and physical activity, and an ‘obesogenic environment’ that shapes those behaviours, have contributed to the spread of childhood obesity [3, 4]. In the last decades, there has been a growing interest in the idea that the early life environment can have lasting effects on the physiology and metabolism of the fetus and is associated with the early metabolic programming of human health [5,6,7]. Recent studies have revealed that several in utero exposures such as maternal socioeconomic status, clinical and environmental factors are associated with growth in infancy and with the subsequent development of childhood overweight or obesity [8,9,10,11,12,13]. The prenatal environment can affect fetus weight homeostasis and may result in a ‘thrifty phenotype’ that stores excess calories and predisposes children to weight gain [14]. Hence, a metabolic signature at birth may help elucidate the mechanisms involved in metabolic health later in life.

Metabolomics, the profiling of circulating small molecules, has been increasingly applied to investigate biological mechanisms associated with childhood obesity [15, 16]. However, few studies have investigated metabolic changes in cord blood that may predict subsequent infant growth and overweight and obesity [17]. Isganaitis, Rifas-Shiman et al. [18] analysed the metabolome in cord blood plasma from 26 cases and 26 controls differing in their postnatal weight trajectories using targeted mass spectrometry (MS) analysis of 415 metabolites, nested in an American cohort. There was a trend for lower levels of tryptophan metabolites in children that followed a rapid growth to obesity at 7 years trajectory. Sorrow, Maguire et al. [19] similarly applied a targeted MS analysis of 384 metabolites in cord blood of 25 obese and non-obese American children at 3–5 years. Children

with obesity had elevated lipid species, acetaminophen metabolites and acylcarnitines compared with non-obese children, although no multiple testing correction was applied. Hellmuth, Uhl et al. [20] applied a range of targeted LC-MS assays to assess 209 metabolites in cord blood of 700 German children in relation to birthweight, postnatal weight gain and BMI throughout adolescence. Although many metabolites were associated with weight at birth, no associations with postnatal measures survived multiple testing correction. Although initial studies have so far been based on small numbers of children or limited numbers of molecules, they reveal the potential of metabolic profiling in detecting biomarkers and pathways related to rapid growth in infancy as well as to overweight and obesity in early childhood. Identifying markers that are predictive of obesity onset may assist in the development of targeted intervention programmes for at-risk groups of children.

In this study, we have investigated the cord blood metabolic signatures of rapid growth in infancy and overweight in early childhood in four European birth cohorts, using untargeted LC-MS-based metabolic profiling. Our aims were twofold: firstly, to identify markers associated with rapid growth and overweight risk to provide mechanistic insight and elucidate causal pathways to obesity; and secondly to improve prediction of obesity risk in neonates through assessment of the predictive performance of models incorporating identified metabolites, in comparison with models based on traditional risk factors alone.

Materials and methods

Study population

The study population included participants from four population-based birth cohorts participating in the STOP project: ENVIRONAGE [21] (Belgium), INMA [22] (Spain), Piccolipiù [23] (Italy) and Rhea [24] (Greece). Ethical approval was obtained from the local Research Ethics Committees from each centre. Informed consent was obtained from the parents of the children. Further details of blood sampling, clinical, dietary and socioeconomic data of cohort individuals are given in the respective references and supporting information 1.

Untargeted metabolomics

Cord blood samples were analysed in randomised order as a single uninterrupted batch with a UHPLC-QTOF-MS system (Agilent Technologies), as previously described [25]. Further details of the acquisition and structural annotation of features are given in supporting information 1.

Outcome assessment

Rapid growth in infants in the first 12 months was categorised based on the definition of Ong et al. [25]. According to this definition, a clinically significant increment that indicates rapid growth occurs when there is a gain in weight of at least 0.67 standard deviations between different target ages. In this study, length data at birth were not available. Hence, rapid growth was defined as the weight z score change of >0.67 standard deviations (SD) between birth and twelve months of age based on World Health Organisation (WHO) growth charts [26]. A two-step prediction approach was used for calculating sex- and age-specific weight at exactly 12 months, using fractional polynomials of age by gender in each cohort [27] (supporting information 1).

To maintain sample size for the analysis of overweight in early childhood, we used a single measurement at an age greater than four years and as close to 6 years as available. The classification for healthy and overweight was based on WHO sex-adjusted and age-adjusted BMI z scores. WHO provides different classifications scheme for children under the age of 5 years (0–5< years) [28] and over the age of 5 years (5–18 years) [29]. Following the WHO proposed classification by De Onis and Lobstein [30], children younger than 5 years were classified as overweight if they had a BMI z scores >1 SD and children over 5 years were classified as overweight if they had a BMI z -score greater than 2 SDs [30].

Statistical analysis

A Metabolome-Wide Association Study (MWAS) was applied to investigate the association between cord blood metabolomics and infant rapid growth/childhood overweight using multiple mixed-effect logistic regression models using the lme4 R package [31]. The basic model (Model 1) was adjusted for sex and age of the child at outcome measurement, ethnicity and we used a random-effect for cohort. To account for multiple testing, a Benjamini–Hochberg false discovery rate (FDR) [32] was applied using a cutoff of 5%.

We then applied additional covariate adjustment to significant features identified in the MWAS analysis. A directed acyclical graph was used to visualise assumptions regarding covariates for further model adjustment (Figure S1). Covariates were chosen based on a bivariate analysis of their correlation with outcomes (Logistic Regression). The resulting model (Model 2) included Model 1 covariates and maternal BMI, paternal BMI, gestational age, weight gained during pregnancy, paternal education, passive and active smoking status during pregnancy, parity and mode of delivery.

Pathway enrichment analysis on significant features was conducted using the *Mummichog* programme [33], supplemented with manual curation of the metabolite identities assigned by *Mummichog* (supporting information 1).

A look-up analysis, using the same statistical approach as the MWAS analysis (including 5% FDR), was conducted on 43 metabolites that had been previously annotated in the same data set as used in this study, due to their associations with birthweight [34, 35] or because they had previously been reported to predict a rapid growth leading to overweight in childhood trajectory, and could also be identified with high confidence through retention time and MS/MS matching in our data set [18].

In sensitivity analyses, we re-ran Model 2 for metabolites associated with rapid growth or overweight, stratified by cohort, sex and size for gestational age and additionally adjusted for birthweight.

We further assessed how well rapid growth in infancy or overweight in early childhood are predicted using metabolites in comparison with traditional factors using Random Forest classification models [36] (supporting information 1). We used three different sets of variables for each of the outcomes: (1) traditional risk factors (sex, birthweight, ethnicity, maternal BMI, paternal BMI, gestational age, maternal weight gain during pregnancy, paternal education, maternal passive and active smoking status during pregnancy, parity and mode of delivery), (2) significantly associated metabolites from the MWAS analysis and (3) significantly associated metabolites from MWAS analysis in combination with traditional risk factors. A bootstrap method of 1000 repetitions was advocated to quantify optimism and evaluate the generalisation of the model. A threefold cross-validation routine was performed on the training set (random 80% of the total observations) to each model to determine the optimum probability threshold. The model performance was evaluated on the relevant test set (remaining 20% of the total observations) using receiver operating characteristic (ROC curve) and area under the curve or AUROC for assessing the goodness-of-fit of the classifier. To further evaluate the predictive model, we performed a leave-one-out analysis by repeating the modelling process on a combined data set with one cohort retained as the validation set (supporting information 1).

Results

Participant Information and metabolomic data

Table 1 shows the characteristics of the population used in the analysis of rapid growth in infancy and overweight in early childhood (stratification by cohort, including available dietary information, is presented in Table S1, S2. In bivariate analyses (Table 1), birthweight, parity, maternal weight gained during pregnancy, mode of delivery and gestational age were all significantly associated ($P < 0.05$) with rapid growth, while maternal passive and active smoking during pregnancy, maternal BMI, paternal education level, paternal BMI and rapid growth in infancy were significantly associated with overweight in early childhood. After data filtering procedures, 4714 metabolic features were available for statistical analysis.

Cord blood metabolomics and rapid growth in the first year of life

The analysis of rapid growth included 391 children, with 114 (28.9%) classed as rapid growers in the first year of life. In MWAS analysis, adjusting for age at the outcome measurement, sex, cohort and ethnicity (Model 1), six metabolic features were significantly associated ($FDR < 5\%$) with rapid growth in the first year of life (Fig. 1A). Table S3 contains the retention time as well as the exact mass of all significantly associated features, including unassigned metabolites. The metabolic features were grouped into four metabolites after grouping of ions originating from the same molecule (matched by retention time and pairwise feature correlation, Table S3). One metabolite could be identified as cholestenone (4-cholesten-3-one; HMDB0000921), a steroid lipid in the class of cholesterol. Upon adjustment for further covariates (Model 2), three of the four associated metabolites, including cholestenone, remained significantly associated with rapid growth (Fig. 2A). Cholestenone levels were higher in the cord blood of rapid growers, whereas levels of the rest of the metabolites were lower in the cord blood of rapid growers.

In a look-up analysis, we analysed associations with 43 known metabolites (retention time and m/z information given in Table S4) in the metabolome data set that had been previously annotated based on their associations with birthweight [34, 35], or with rapid infancy weight gain and childhood obesity [18] (including indolelactic acid, sphingosine, tryptophan and leucine)(Table S5). Fourteen metabolites were associated with rapid growth in the first year of life (Fig. 2B) after correcting for 5% FDR in basic adjustment analyses (Model 1), including higher levels of nine phosphatidylcholines (PCs) or LysoPCs, cholestenone, cholesterol, progesterone and two acylcarnitines tetradecadiencarnitine (C14:2) and decenoylcarnitine (C10:1). In additionally adjusted analyses (Model 2) cholestenone, two PCs (PC(34:2) and plasmalogen PC(36:4)/PC(O-36:5)), two acylcarnitines, docosahexaenoic acid (DHA), diacylglycerol (C36:4) and progesterone

were nominally associated ($P < 0.05$) with rapid growth (Fig. 2B). Directions of association with rapid growth were opposite to directions observed previously with birthweight [34]. Correcting Model 2 for 5% FDR, only cholestenone remained associated with rapid growth in the first year of life.

As shown in the network graph (Fig. 2C), cholestenone was highly correlated with PC(34:2), moderately correlated with unidentified metabolite U4 and had weaker, positive correlations with the other rapid growth-associated metabolites. We noted strong correlations between DHA and plasmalogen PC(36:4)/PC(O-36:5) as well as between tetradecadiencarnitine (C14:2) and PC(34:2).

Mummichog analysis indicated enrichment among rapid growers in the ‘C21-steroid hormone biosynthesis and metabolism’ and ‘Androgen and oestrogen biosynthesis and metabolism’ pathways, with weaker support for enrichment of the ‘Urea cycle/amino group metabolism’ pathway (supporting information 1 and 2, Table S10).

Cord blood metabolomics and overweight in early childhood

The analysis of child overweight in early childhood included 272 children from the Piccolipiu, Rhea and INMA cohorts, of which 48 (17.6%) were classed as being overweight or obese (mean age at weight status assessment: 5.12 years (SD:1.11)). In the MWAS, adjusting for cohort and ethnicity (Model 1), 36 features were significantly associated ($FDR < 5\%$) with overweight in early childhood (Fig. 1B). After grouping ions originating from the same compound (Table S6), there were eight unique compounds associated with overweight (Fig. 3A). One compound could be annotated as valine, a branched-chain amino acid. Retention time as well as exact mass of all significantly associated features, including unassigned compounds, are available in Table S6. The inverse association of valine with overweight was strengthened upon additional covariate adjustment (Model 2) and remained significant after FDR correction.

In an analysis of the 43 pre-annotated metabolites, leucine and DHA were nominally associated ($P < 0.05$) with overweight in basic analyses (Model 1) (Fig. 2B). In additionally adjusted analyses (Model 2) lower levels of leucine, progesterone, indolelactic acid, hexenoylcarnitine (C6:1), hexadecenoylcarnitine (C16:1) and DHA were nominally associated ($P < 0.05$) with overweight in early childhood (Table S7). Directions of association with overweight were consistent with directions observed previously with birthweight [34]. Only leucine, a BCAA previously identified

in relation to rapid infancy weight gain and childhood obesity by Isganaitis, Rifas-Shiman et al. [18], remained significant after FDR correction.

Valine was moderately correlated with DHA and had weaker correlations with the unidentified compounds U4, U5 and U7 and stronger correlations with U3 and hexadecenoylcarnitine (C16:1). Leucine had a weak negative correlation with Valine and strong negative correlations with U1, U4, U5 and U7. Strong correlations were observed between progesterone and indolelactic acid as well as between the compounds U1, U4, U5 and U7 (Fig. 3C).

Mummichog analysis did not provide strong support for enrichment of specific pathways with childhood overweight (supporting information 1 and 3, Table S11).

Multivariate prediction models

We next utilised Random Forest classification models to evaluate the predictive performance of three different input variable sets for each of the two outcomes (Fig. 4). The rapid growth prediction model trained using only traditional risk factors exhibited a moderate predictive ability of an AUROC value of 0.69 (bootstrap 95% confidence interval (CI):0.62–0.77) (Table S8). Adding the four metabolites (cholestenone, U2, U4 and U8) identified in the MWAS analysis into the prediction model, increased the AUROC to 0.77 (bootstrap 95% CI: 0.73–0.81) (Fig. 4A). For overweight, using traditional risk factors alone, the AUROC was 0.69 (bootstrap 95%CI: 0.63–0.75), while a model using only the eight metabolites, Valine, U1, U2, U3, U4, U5, U7 and U9, identified in the MWAS analysis had an AUROC of 0.77 (bootstrap 95% CI: 0.73–0.81) (Table S8). The combined traditional risk factor and metabolite model was strongly predictive of overweight with an AUROC of 0.82 (bootstrap 95% CI: 0.79–0.85) (Fig. 4B). The leave cohort out analysis also showed improvement in predictive performance using metabolites, in the majority of cohorts (Table S9).

Sensitivity analysis

To assess the robustness and consistency of our results, we stratified our population by cohort and by sex and repeated the adjusted models (Model 2) across each subpopulation. Regarding rapid growth, results were generally consistent across cohorts for all identified metabolites, including cholesterol (Figure S2). However, opposite directions of effects were observed in the Piccolipiu cohort for PC(34:2) and plasmalogen PC(36:4)/PC(O-36:5). Regarding overweight, results were again consistent across cohorts (Figure S3), although wide confidence intervals were observed in

Piccolipiu (related to the small number of overweight cases available in this cohort). For valine, strong associations were noted in both the INMA and Rhea cohorts. For rapid growth, stronger associations were observed in boys with PC(34:2) and diacylglycerol (C36:4), while in girls stronger associations with rapid growth were observed with progesterone, tetradecadiencarnitine (C14:2), decenoylcarnitine(C10:1) and DHA (Figure S4). Very similar associations were seen with overweight upon stratification by sex (Figure S5).

To assess the role of birthweight in observed associations, we additionally adjusted our models for birthweight. There was some attenuation in effect size in associations for rapid growth (Figure S6), however, the attenuation with cholestenone was modest and significance was retained. Adjustment for birthweight had little effect on associations with overweight (Figure S7). Upon stratification by size for gestational age (< and \geq 33rd percentile of birthweight for gestational age, Figure S8) we observed stronger associations with cholestenone and rapid growth as well as DHA and rapid growth among larger for gestational age (\geq 33rd percentile) infants. We noted stronger associations with hexadecenoylcarnitine (C16:1), hexenoylcarnitine(C6:1), leucine and valine and overweight among smaller for gestational age (<33rd percentile) infants (Figure S9).

Discussion

This is the first study to date that investigates the association between untargeted metabolic profiles of cord blood and rapid growth at the first year of life and overweight/obesity in early childhood. We identified cholestenone and BCAA levels in cord blood as predictive of rapid growth and overweight/obesity, respectively, among healthy deliveries from four European populations. In multivariate analysis, we found that the addition of metabolites substantially improved prediction of both rapid growth and overweight compared with models using traditional risk factors alone.

Higher levels of cholestenone were identified as predictive of rapid growth in the MWAS analysis, with consistent effects noted across the four included cohorts. Little is known about the effects of cholestenone on health. It has previously been reported to be associated with CpG sites that are differentially methylated in relation to birthweight [35], however, birthweight did not appear to be an important contributor to the relationship between cholestenone and rapid growth in our study. Supplementation of diet with cholestenone leads to growth retardation in rodents and high levels cause hypertrophy of the adrenal glands, which may suggest potential endocrine effects [37, 38]. Cholestenone is produced by bacterial catabolism of cholesterol in the intestinal tract [39]. It therefore may be serving as a proxy indicator of the relative abundance of various microbiota present at birth, although the infant gut microbiome is generally uniform and under-developed at

this stage [40]. Indeed, gestational age, which is known to influence the composition of the neonatal gut microbiome [41], was strongly associated with cholestenone levels in our data. However, the strong association between cholestenone and rapid growth remained after adjustment for gestational age. The role of the gut microflora in obesity is increasingly recognised [42] and differences in faecal microbiota composition measured during the first year of life have been found to be associated with weight status in later childhood [43].

Lower levels of the BCAAs valine and leucine were associated with overweight/obesity in early childhood, with consistent effects across both the Rhea and INMA cohorts. Associations were somewhat stronger with valine than leucine. Lower levels of cord blood leucine were also identified as nominally associated with children on a rapid growth trajectory by the study of Isganaitis, Rifas-Shiman et al. [18]. This is in contrast with the study of Hellmuth et al., where no associations were reported between BCAAs in cord blood and weight status at 2 and 10 years, although the authors speculated that the long storage period in their study may have degraded certain metabolites such as amino acids. BCAAs levels in cord blood represent the balance of supply, from the mother and from protein degradation, and of clearance through protein synthesis, excretion and BCAA catabolism and/or oxidation. BCAAs have a complex relationship with overweight and obesity. On one hand, higher levels in blood are consistently associated with obesity, insulin resistance and type 2 diabetes. Adjustment for maternal BMI, which would be expected to increase maternal levels and the fetal supply of BCAAs, strengthened the association between cord blood BCAA levels and childhood overweight, suggesting some negative confounding. On the other hand, numerous intervention studies and animal studies have shown that increasing dietary intake of BCAAs has beneficial signalling effects, with positive effects on parameters including body composition, glycemia and satiety [44]. Multiple mechanisms for these positive effects have been proposed including direct effects on hypothalamic and brainstem processes involved in satiety [44]. Cord blood BCAAs levels could therefore influence later propensity for overweight through causal processes such as control of food intake or alternatively serve as a marker of other metabolic processes that influence both propensity for weight gain and levels of BCAAs.

Apart from the association between leucine and overweight, no other associations were observed for metabolites identified by Isganaitis, Rifas-Shiman et al. [18]. Among metabolites previously identified as associated with birthweight, we identified higher levels of progesterone, PC(34:2), plasmalogen PC(36:4)/PC(O-36:5), DHA, decenoylcarnitine (C10:1), tetradecadienecarnitine (C14:2) and diacylglycerol (C36:4) as nominally associated with rapid growth, although these did not pass multiple testing correction. Progesterone is the major progestational hormone involved

throughout all stages of pregnancy, and the pathway enrichment analysis also highlighted the role of hormonal signalling in rapid growth. DHA supplementation in milk has been shown to increase growth among preterm infants [45]. For overweight in early childhood, we noted nominal associations with lower levels of progesterone, indolelactic acid, hexenoylcarnitine (C6:1), hexadecenoylcarnitine (C16:1) and DHA. Indolelactic acid is a tryptophan catabolite that has an important role in the pathophysiology of obesity [46, 47] and is produced entirely by gut microbes [48]. Hexadecenoylcarnitine (C16:1) levels in the blood have been associated with obesity in children [49], while positive effects of DHA on obesity risk and metabolic health have been noted by multiple studies [50, 51], with proposed mechanisms including suppression of fatty-acid synthesis, enhancement of fatty-acid β -oxidation and increase of the serum adiponectin level [52]. The relatively small overlap in cord blood metabolites associated with birthweight and with rapid growth and with obesity, suggests that different mechanisms underlie these outcomes. Furthermore, despite the established association with rapid growth in infancy and later development of overweight, the different directions of effect in birthweight-related metabolites, observed with these two outcomes, suggest different contributory processes. Indeed, lower birthweight was a strong predictor of rapid growth while there was a trend for larger birthweight being associated with overweight in childhood.

Our analysis using a Random Forest classification model revealed that the coupling of the strongly associated molecules and demographic and clinical factors has a high ability to predict overweight/obesity in early childhood. Isganaitis, Rifas-Shiman et al. [18] suggested that cord blood metabolic signatures could be associated with early childhood obesity trajectories demonstrating, in a similar way with our analysis, that prediction models based on prenatal obesity factors (maternal age, pre-pregnancy BMI and breastfeeding duration) can be improved by adding cord blood associated metabolites. Although models would need to be validated in cohorts that are independent of the selection of metabolites, our results highlight a potential practical application of metabolomics to identify children at risk of obesity and support the potential merit of routine screening of cord blood [53].

A strength of our study includes the use of cord blood from multiple birth cohorts, enabling assessment of the metabolome prior to infant growth, limiting reverse causality. We included a number of prenatal sociodemographic and clinical factors in our analysis. However, we did not have complete data related to maternal nutrition and physical activity that could be linked to both the metabolome and the family environment later in life. Nevertheless, we used paternal socioeconomic factors and maternal clinical factors such as BMI that can reflect general patterns of family nutrition

[54] and physical activity [55,56,57]. Future studies, with high-quality dietary data available, should explore the role of maternal nutrition on the cord blood metabolome.

Although the samples were analysed within a single analytical run in random order, we observed heterogeneity across the cohort metabolomic signatures, mainly explained by the processing of cord blood into plasma or serum. This heterogeneity can influence the observed associations, and for this reason, we added in the model a random effect variable for the cohort. Another limitation was that the sample was selected from the general population and we, therefore, had a relatively low number of overweight children. Furthermore, the use of BMI *z* scores to classify children as overweight is a blunter assessment of adiposity than direct measures such as dual-energy X-ray absorptiometry [58]. We used WHO obesity classification criteria, which have higher sensitivity and lower specificity in identifying obese subjects than the International Obesity Task Force cutoffs. The untargeted approach is both a strength and limitation: while it provides wide metabolome coverage [59], identification of the features can be challenging. Indeed, we were also unable to characterise all the significant features in the MWAS analysis.

Conclusion

We have demonstrated metabolic profiles associated with rapid growth in infancy and overweight/obesity in early childhood, highlighting the role of multiple metabolites in various pathways. We presented evidence that cholestenone and BCAAs are associated with rapid growth in infancy and overweight/obesity in early childhood, respectively, and provide new insights on the potential mechanism underlying overweight risk, particularly early in development. Our findings present a potential route to the identification of at-risk children for the provision of targeted interventions to improve outcomes for children living in obesogenic environments.

References

1. Abarca-Gómez L, Abdeen ZA, Hamid ZA, Abu-Rmeileh NM, Acosta-Cazares B, Acuin C, et al. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. *Lancet*. 2017;390:2627–42.
2. Segal AB, Huerta MC, Aurino E, Sassi F. The impact of childhood obesity on human capital in high-income countries: a systematic review. *Obes Rev*. 2020;22:e13104.

3. Liu J-H, Jones SJ, Sun H, Probst JC, Merchant AT, Cavicchia P. Diet, physical activity, and sedentary behaviors as risk factors for childhood obesity: an urban and rural comparison. *Child Obes.* 2012;8:440–8.
4. Patrick K, Norman GJ, Calfas KJ, Sallis JF, Zabinski MF, Rupp J, et al. Diet, physical activity, and sedentary behaviors as risk factors for overweight in adolescence. *Arch Pediatr Adolesc Med.* 2004;158:385–90.
5. Demetriou CA, van Veldhoven K, Relton C, Stringhini S, Kyriacou K, Vineis P. Biological embedding of early life exposures and disease risk in humans: a role for DNA methylation. *Eur J Clin Invest.* 2015;45:303–32.
6. Barker DJ, Osmond C. Infant mortality, childhood nutrition, and ischaemic heart disease in England and Wales. *Lancet.* 1986;327:1077–81.
7. Godfrey KM. Maternal regulation of fetal development and health in adult life. *Eur J Obstet Gynecol Reprod Biol.* 1998;78:141–50.
8. Huang JS, Lee TA, Lu MC. Prenatal programming of childhood overweight and obesity. *Matern Child Health J.* 2007;11:461–73.
9. Yu Z, Han S, Zhu J, Sun X, Ji C, Guo X. Pre-pregnancy body mass index in relation to infant birth weight and offspring overweight/obesity: a systematic review and meta-analysis. *PLoS ONE.* 2013;8:e61627.
10. Oken E, Levitan E, Gillman M. Maternal smoking during pregnancy and child overweight: systematic review and meta-analysis. *Int J Obes.* 2008;32:201–10.
11. Chen A, Pennell ML, Klebanoff MA, Rogan WJ, Longnecker MP. Maternal smoking during pregnancy in relation to child overweight: follow-up to age 8 years. *Int J Epidemiol.* 2006;35:121–30.
12. Vafeiadi M, Roumeliotaki T, Myridakis A, Chalkiadaki G, Fthenou E, Dermitzaki E, et al. Association of early life exposure to bisphenol A with obesity and cardiometabolic traits in childhood. *Environ Res.* 2016;146:379–87.
13. Mao G, Nachman RM, Sun Q, Zhang X, Koehler K, Chen Z, et al. Individual and joint effects of early-life ambient PM 2.5 exposure and maternal prepregnancy obesity on childhood overweight or obesity. *Environ Health Perspect.* 2017;125:067005.
14. Kim JT, Lee HK. Metabolic syndrome and the environmental pollutants from mitochondrial perspectives. *Rev Endocr Metab Disord.* 2014;15:253–62.

15. Leal-Witt M, Ramon-Krauel M, Samino S, Llobet M, Cuadras D, Jimenez-Chillaron J, et al. Untargeted metabolomics identifies a plasma sphingolipid-related signature associated with lifestyle intervention in prepubertal children with obesity. *Int J Obes.* 2018;42:72–78.
16. Lau C-HE, Siskos AP, Maitre L, Robinson O, Athersuch TJ, Want EJ, et al. Determinants of the urinary and serum metabolome in children from six European populations. *BMC Med.* 2018;16:202.
17. Handakas E, Keski-Rahkonen P, Chatzi L, Alfano R, Roumeliotaki T, Plusquiz M et al. Cord blood metabolic signatures predictive of childhood overweight and rapid growth. *Obes Rev.* Under review.
18. Isganaitis E, Rifas-Shiman SL, Oken E, Dreyfuss J, Gall W, Gillman MW, et al. Associations of cord blood metabolites with early childhood obesity risk. *Int J Obes.* 2015;39:1041–8.
19. Sorrow P, Maguire R, Murphy SK, Belcher SM, Hoyo C. Elevated metabolites of acetaminophen in cord blood of children with obesity. *Pediatr Obes.* 2019;14:e12465.
20. Hellmuth C, Uhl O, Standl M, Demmelmair H, Heinrich J, Koletzko B, et al. Cord blood metabolome is highly associated with birth weight, but less predictive for later weight development. *Obes Facts.* 2017;10:85–100.
21. Janssen BG, Madhloum N, Gyselaers W, Bijmens E, Clemente DB, Cox B, et al. Cohort profile: the ENVIRONMENTAL influence ON early AGEing (ENVIR ON AGE): a birth cohort study. *Int J Epidemiol.* 2017;46:1386–1387m.
22. Guxens M, Ballester F, Espada M, Fernández MF, Grimalt JO, Ibarluzea J, et al. Cohort profile: the INMA—INfancia y Medio Ambiente—(environment and childhood) project. *Int J Epidemiol.* 2011;41:930–40.
23. Farchi S, Forastiere F, Vecchi Brumatti L, Alviti S, Arnofi A, Bernardini T, et al. Piccolipiù, a multicenter birth cohort in Italy: protocol of the study. *BMC Pediatr.* 2014;14:36–36.
24. Chatzi L, Leventakou V, Vafeiadi M, Koutra K, Roumeliotaki T, Chalkiadaki G, et al. Cohort profile: the mother-child cohort in Crete. Greece (Rhea study). 2017;46:1392–1393k.
25. Ong KK, Ahmed ML, Emmett PM, Preece MA, Dunger DBJB. Association between postnatal catch-up growth and obesity in childhood. prospective cohort study. 2000;320:967–71.
26. GROUP WMGRS, de Onis M. WHO Child Growth Standards based on length/height, weight and age. *Acta Paediatr.* 2006;95:76–85.

27. Royston P, Wright EM. A method for estimating age-specific reference intervals ('normal ranges') based on fractional polynomials and exponential transformation. *J R Statist Soc.* 1998;161:79–101.
28. World Health Organization. WHO child growth standards: training course on child growth assessment. 2008.
29. De Onis M. WHO child growth standards. Geneva: WHO 2006: 1Á336.
30. De Onis M, Lobstein T. Defining obesity risk status in the general childhood population: which cut-offs should we use? In: Taylor & Francis, 2010.
31. Bates D, Maechler M, Bolker B, Walker S. lme4: Linear mixed-effects models using Eigen and S4. R package version 2014;1:1–23.
32. Benjamini Y, YJJotRsssB Hochberg. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Statist Soc.* 1995;57:289–300.
33. Li S, Park Y, Duraisingham S, Strobel FH, Khan N, Soltow QA, et al. Predicting network activity from high throughput metabolomics. *PLoS Comput Biol.* 2013;9:e1003123.
34. Robinson O, Keski-Rahkonen P, Chatzi L, Kogevinas M, Nawrot T, Pizzi C, et al. Cord blood metabolic signatures of birth weight: a population-based study. *J Proteome Res.* 2018;17:1235–47.
35. Alfano R, Chadeau-Hyam M, Ghantous A, Keski-Rahkonen P, Chatzi L, Perez AE, et al. A multi-omic analysis of birthweight in newborn cord blood reveals new underlying mechanisms related to cholesterol metabolism. *Metabolism.* 2020;110:154292.
36. Breiman L. Random forests. *Mach Learn.* 2001;45:5–32.
37. Suzuki K, Shimizu T, Nakata T. The cholesterol metabolite cholest-4-en-3-one and its 3-oxo derivatives suppress body weight gain, body fat accumulation and serum lipid concentration in mice. *Bioorg Med Chem Lett.* 1998;8:2133–8.
38. Degenhart H, Alsema G, Visser H. Effects of cholestenone feeding in rats. *Pediatr Res.* 1981;15:78–78.
39. Kenny DJ, Plichta DR, Shungin D, Koppel N, Hall AB, Fu B, et al. Cholesterol metabolism by uncultured human gut bacteria influences host cholesterol level. *Cell Host Microbe.* 2020;28:245–257.e6.
40. Moore RE, Townsend SD. Temporal development of the infant gut microbiome. *Open Biol.* 2019;9:190128.

41. Cong X, Xu W, Janton S, Henderson WA, Matson A, McGrath JM, et al. Gut microbiome developmental patterns in early life of preterm infants: impacts of feeding and gender. *PLoS ONE*. 2016;11:e0152751.
42. Groer MW, Luciano AA, Dishaw LJ, Ashmeade TL, Miller E, Gilbert JA. Development of the preterm infant gut microbiome: a research priority. *Microbiome*. 2014;2:38.
43. Kalliomäki M, Collado MC, Salminen S, Isolauri E. Early differences in fecal microbiota composition in children may predict overweight. *Am J Clin Nutr*. 2008;87:534–8.
44. Lynch CJ, Adams SH. Branched-chain amino acids in metabolic signalling and insulin resistance. *Nat Rev Endocrinol*. 2014;10:723–36.
45. Clandinin MT, Van Aerde JE, Merkel KL, Harris CL, Springer MA, Hansen JW, et al. Growth and development of preterm infants fed infant formulas containing docosahexaenoic acid and arachidonic acid. *J Pediatr*. 2005;146:461–8.
46. Sun L, Ma L, Ma Y, Zhang F, Zhao C, Nie Y. Insights into the role of gut microbiota in obesity: pathogenesis, mechanisms, and therapeutic perspectives. *Protein Cell*. 2018;9:397–403.
47. Ni Y, Ni L, Zhuge F, Fu Z. The gut microbiota and its metabolites, novel targets for treating and preventing non-alcoholic fatty liver disease. *Mol Nutr Food Res*. 2020;64:2000375.
48. Agus A, Planchais J, Sokol H. Gut microbiota regulation of tryptophan metabolism in health and disease. *Cell Host Microbe*. 2018;23:716–24.
49. Wahl S, Yu Z, Kleber M, Singmann P, Holzapfel C, He Y, et al. Childhood obesity is associated with changes in the serum metabolite profile. *Obes Facts*. 2012;5:660–70.
50. Simopoulos AP. An increase in the omega-6/omega-3 fatty acid ratio increases the risk for obesity. *Nutrients*. 2016;8:128.
51. Kunešová M, Braunerová R, Hlavatý P, Tvrzická E, Staňková B, Škrha J et al. The influence of n-3 polyunsaturated fatty acids and very low calorie diet during a short-term weight reducing regimen on weight loss and serum fatty acid composition in severely obese women. *Physiol Res*. 2006;55:63–72.
52. Shirouchi B, Nagao K, Inoue N, Ohkubo T, Hibino H, Yanagita T. Effect of dietary omega 3 phosphatidylcholine on obesity-related disorders in obese Otsuka Long-Evans Tokushima fatty rats. *J Agric Food Chem*. 2007;55:7170–6.
53. Kelly N, Makarem DC, Wasserstein MP. Screening of newborns for disorders with high benefit-risk ratios should be mandatory. *J Law Med Ethics*. 2016;44:231–40.

54. Williams JE, Helsel B, Griffin SF, Liang J. Associations between parental BMI and the family nutrition and physical activity environment in a community sample. *J Commun Health*. 2017;42:1233–9.
55. McMurray RG, Harrell JS, Deng S, Bradley CB, Cox LM, Bangdiwala SI. The influence of physical activity, socioeconomic status, and ethnicity on the weight status of adolescents. *Obes Res*. 2000;8:130–9.
56. Yang XL, Telama R, Laakso L. Parents' physical activity, socioeconomic status and education as predictors of physical activity and sport among children and youths-A 12-year follow-up study. *Int Rev Soc Sport*. 1996;31:273–91.
57. Lampinen E-K, Eloranta A-M, Haapala EA, Lindi V, Väistö J, Lintu N, et al. Physical activity, sedentary behaviour, and socioeconomic status among Finnish girls and boys aged 6–8 years. *Eur J Sport Sci*. 2017;17:462–72.
58. Freedman DS, Sherry B. The validity of BMI as an indicator of body fatness and risk among children. *Pediatrics*. 2009;124:S23–S34.
59. Sun YV, Hu Y-J. Integrative analysis of multi-omics data for discovery and functional studies of complex human diseases. *Adv Genet*. 2016;93:147–90.

Acknowledgements

This research was supported by European Commission Horizon 2020 Grant to the ‘STOP Project’ (Grant ref. 774548). This study was funded by the European Union Social Fund and the Hellenic Ministry of Health (“Programme of prevention and early diagnosis of obesity and neurodevelopment disorders in preschool-age children in the prefecture of Heraklion, Crete, Greece’ MIS number 349580, NSRF 2007-2013). Additional funding from the National Institute of Environmental Health Sciences (NIEHS) supported Dr. Chatzi (R01ES030691, R01ES029944, R01ES030364, R21ES029681, R21ES028903 and P30ES007048). The ENVIRONAGE birth-cohort is supported by the EU Program ‘Ideas’ (ERC-2012-StG-310898) and the FWO (G082317N), a PhD fellowship of the Bijzonder Onderzoeksfonds (BOF) at Hasselt University supported MD Alfano. We acknowledge support from the Spanish Ministry of Science, Innovation and Universities, ‘Centro de Excelencia Severo Ochoa 2013-2017’, SEV-2012-0208 and ‘Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de

Catalunya' (2017SGR595). O.R. was supported by a UKRI Future Leaders Fellowship (MR/S03532X/1).

Author information

Affiliations

1. Medical Research Council Centre for Environment and Health, School of Public Health, Imperial College London, London, UK

Evangelos Handakas, Rossella Alfano, Paolo Vineis & Oliver Robinson

2. Nutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France

Pekka Keski-Rahkonen, Augustin Scalbert & Nivonirina Robinot

3. Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

Lida Chatzi

4. Centre for Environmental Sciences, Hasselt University, Diepenbeek, Belgium

Rossella Alfano, Michelle Plusquin & Tim Nawrot

5. Department of Social Medicine, Faculty of Medicine, University of Crete, Heraklion, Greece

Theano Roumeliotaki

6. Barcelona Institute of Global Health (ISGlobal), Barcelona, Spain

Léa Maitre & Martine Vrijheid

7. Universitat Pompeu Fabra, Barcelona, Spain

Léa Maitre & Martine Vrijheid

8. CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain

Léa Maitre & Martine Vrijheid

9. Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO □ Piemonte, Torino, Italy

Lorenzo Richiardi

10. Centre for Behavioural Science and Mental Health, Istituto Superiore di Sanità, Rome, Italy

Sonia Brescianini

11. Centre for Health Economics & Policy Innovation, Department of Economics & Public Policy, Imperial College Business School, South Kensington Campus, London, UK

Franco Sassi

Contributions

O.R., L.C. and P.V. conceived the study. E.H. performed most statistical analyses. E.H. and O.R. draughted the manuscript. P.K.R., N.R. and A.S. acquired the MSy data and conducted structural annotation. T.R. contributed additional analyses for age prediction models. M.P. and T.N. coordinated data/sample collection in ENVIRONAGE, S.B. and L.R. coordinated data/sample collection in Piccolipiu, L.M. and M.V. coordinated data/sample collection in INMA, T.R. and L.C. coordinated data/sample collection in Rhea, R.A., E.H. and O.R. prepared and supervised data collection and curation. O.R. coordinated and supervised. All authors critically reviewed the manuscript.

1 Cord blood metabolic signatures
2 predictive of childhood overweight and
3 rapid growth
4

5 Evangelos Handakas¹, Pekka Keski-Rahkonen², Lida Chatzi³, Rossella Alfano^{1,4}, Theano
6 Roumeliotaki⁵, Michelle Plusquin⁴, Léa Maitre^{6,7,8}, Lorenzo Richiardi⁹, Sonia Brescianini¹⁰,
7 Augustin Scalbert², Nivonirina Robinot², Tim Nawrot⁴, Franco Sassi¹¹, Martine Vrijheid^{6,7,12},
8 Paolo Vineis¹, Oliver Robinson^{1,*}

9 ¹Medical Research Council Centre for Environment and Health, School of Public Health, Imperial College London, London,
10 United Kingdom

11 ²Nutrition and Metabolism Section, International Agency for Research on Cancer, Lyon, France

12 ³Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, United States of
13 America

14 ⁴Centre for Environmental Sciences, Hasselt University, Diepenbeek, Belgium

15 ⁵Department of Social Medicine, Faculty of Medicine, University of Crete, Heraklion, Greece

16 ⁶Barcelona Institute of Global Health (ISGlobal), Barcelona, Spain

17 ⁷Universitat Pompeu Fabra, Barcelona, Spain

18 ⁸CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain

19 ⁹Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Torino, Italy

20 ¹⁰Centre for Behavioural Science and Mental Health, Istituto Superiore di Sanità, Rome, Italy

21 ¹¹Centre for Health Economics & Policy Innovation, Department of Economics & Public Policy, Imperial College Business
22 School, South Kensington Campus, London, UK

23 ¹² Consorcio de Investigacion Biomedica en Red de Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain

24 Supporting information

25 Table of contents

26	Supporting information.....	2
27	1. Study population.....	20
28	2. Untargeted metabolomics.....	22
29	3. Random Forest and model evaluation for optimism.....	23
30	4. Metabolic pathway enrichment analysis.....	26
31	5. Modelling of weight and height growth trajectories.....	26
32	References.....	31
33		

34 List of figures and tables

35	Table S1: Demographic, anthropometric and clinical outcome variables.....	4
36	Table S2: Individual number, observation number, demographic, anthropometric and clinical	
37	outcome variables average values (standard deviation) or percent (%) for overweight	
38	throughout early childhood by cohort.....	5
39	Table S3: All metabolomic features significantly associated (FDR 5%) with rapid growth at in	
40	first year of life.	6
41	Table S4: Pre-annotated metabolites in cord blood that have been previously identified in the	
42	same dataset associated with birthweight (Robinson et al.; Alfano et al.), or because	
43	they have previously been reported to predict rapid growth leading to overweight in	
44	childhood trajectory (Isganaitis et al.).....	7
45	Table S5: Logistic regression odds ratio per standard deviation (95% CI) for rapid growth at	
46	twelve months for Model 1* and 2** for the birthweight related metabolites.....	8
47	Table S6: All metabolomic features significantly associated (FDR 5%) with	
48	overweight/obesity at early childhood.....	9
49	Table S7: Logistic regression odds ratio per standard deviation (95% CI) for	
50	overweight/obesity in early childhood for Model 1* and 2** for the birthweight related	
51	metabolites.	10
52	Figure S1: Directed acyclical graph (DAG) to visualise assumptions regarding covariates,	
53	metabolome and outcome.....	11
54	Figure S2: Logistic regression odds ratio per standard deviation (95% CI) for rapid growth for	
55	Model 2 stratified by cohort.....	12
56	Figure S3: Logistic regression odds ratio per standard deviation (95% CI) for	
57	overweight/obesity in early childhood for Model 2 stratified by cohort.....	13
58	Figure S4: Logistic regression odds ratio per standard deviation (95% CI) for rapid growth for	
59	Model 2 stratified by sex.	14
60	Figure S5: Logistic regression odds ratio per standard deviation (95% CI) for	
61	overweight/obesity in early childhood for Model 2 stratified by sex.....	15
62	Figure S6: Logistic regression odds ratio per standard deviation (95% CI) for rapid growth at	
63	twelve months for Model 1, Model 2, and Model 3 for the 7 nominal statistically	
64	significant birthweight related metabolites and the 4 associated with rapid growth at	
65	twelve months.....	16
66	Figure S7: Logistic regression odds ratio per standard deviation (95% CI) for	
67	overweight/obesity in early childhood for Model 1, Model 2 and Model 3 for the 6	
68	nominal statistically significant birthweight related metabolites and the 8 associated	
69	with overweight/obesity in early childhood.....	17

70	Figure S8: Logistic regression odds ratio per standard deviation (95% CI) for rapid growth for Model 2 stratified by Small of Gestational Age (SGA)	18
71		
72	Figure S9: Logistic regression odds ratio per standard deviation (95% CI) for overweight/obesity in early childhood for Model 2 stratified by Small of Gestational Age (SGA)	19
73		
74	Table S8: Summary of rapid growth and 12 months of age and overweight/obesity in childhood. Average AUROC across 1000 bootstrapped test sets for all the cohorts. ..	24
75		
76	Table S9: Summary of rapid growth and 12 months of age and overweight/obesity in childhood. Average ROC and CI95% across 1000 bootstrapped test sets using and leave-cohort-out approach.....	24
77		
78	Figure S10: PCA analysis of the whole metabolome and scatter plot of first two principal components, coloured by cohort.....	25
79		
80	Table S10: Mummichog analysis statistically significant pathways for rapid growth at 12 months of age.	27
81		
82	Table S11: Mummichog analysis statistically significant pathways for overweight/obesity in early childhood.....	28
83		
84	Table S12: Comparison of prediction concordance from different fractional polynomial powers for sex-specific weight and height in participating cohorts.	29
85		
86	Figure S11: Actual vs Predicted values of weight and height in participating ENVIRONAGE cohort.....	29
87		
88	Figure S12: Actual vs Predicted values of weight and height in participating INMA cohort. ...	30
89		
90	Figure S13: Actual vs Predicted values of weight and height in participating Piccolipiu cohort.	30
91		
92	Figure S14: Actual vs Predicted values of weight and height in participating RHEA cohort. .	31
93		
94		

Table S1: Demographic, anthropometric and clinical outcome variables. Values are given in mean (standard deviation, SD) or percent (%) for rapid growth at twelve months of age by cohort.

	RHEA (n=100)	Missing	ENVIRONAGE (n=109)	Missing	Piccolipiu (n=95)	Missing	INMA (n=87)	Missing
cohort								
RHEA	100 (100%)		-		-		-	
ENVIRONAGE	-		109 (100%)		-		-	
Piccolipiu	-		-		95 (100%)		-	
INMA	-		-		-		87 (100%)	
gender								
male	53 (53.0%)		55 (50.5%)		54 (56.8%)		42 (48.3%)	
female	47 (47.0%)		54 (49.5%)		41 (43.2%)		45 (51.7%)	
maternal parity before this pregnancy		2 (2.0%)		0 (0%)		0 (0%)		1 (1.1%)
nulliparous	28 (28.0%)		65 (59.6%)		45 (47.4%)		44 (50.6%)	
uniparous	47 (47.0%)		44 (40.4%)		42 (44.2%)		36 (41.4%)	
multiparous	23 (23.0%)		0 (0%)		8 (8.4%)		6 (6.9%)	
maternal age		0 (0%)		0 (0%)		1 (1.1%)		0 (0%)
Mean (SD)	30.0 (4.99)		29.1 (3.63)		33.3 (4.46)		31.7 (4.03)	
mother's education		1 (1.0%)		4 (3.7%)		0 (0%)		0 (0%)
primary school	8 (8.0%)		9 (8.3%)		6 (6.3%)		18 (20.7%)	
secondary school	57 (57.0%)		29 (26.6%)		40 (42.1%)		40 (46.0%)	
university or higher	34 (34.0%)		67 (61.5%)		49 (51.6%)		29 (33.3%)	
father's education		2 (2.0%)		10 (9.2%)		0 (0%)		1 (1.1%)
primary school	21 (21.0%)		10 (9.2%)		16 (16.8%)		23 (26.4%)	
secondary school	57 (57.0%)		45 (41.3%)		43 (45.3%)		44 (50.6%)	
university or higher	20 (20.0%)		44 (40.4%)		36 (37.9%)		19 (21.8%)	
maternal smoking		1 (1.0%)		0 (0%)		0 (0%)		0 (0%)
no	79 (79.0%)		102 (93.6%)		76 (80.0%)		67 (77.0%)	
yes	20 (20.0%)		7 (6.4%)		19 (20.0%)		20 (23.0%)	
passive smoke exposure		5 (5.0%)		2 (1.8%)		0 (0%)		1 (1.1%)
no	13 (13.0%)		100 (91.7%)		74 (77.9%)		46 (52.9%)	
yes	82 (82.0%)		7 (6.4%)		21 (22.1%)		40 (46.0%)	
maternal height (cm)		1 (1.0%)		5 (4.6%)		0 (0%)		1 (1.1%)
Mean (SD)	163 (5.65)		167 (7.07)		164 (5.67)		163 (6.66)	
maternal weight (kg)		1 (1.0%)		0 (0%)		0 (0%)		0 (0%)
Mean (SD)	66.8 (15.6)		67.4 (14.0)		61.1 (11.2)		63.1 (11.5)	
maternal BMI		1 (1.0%)		0 (0%)		0 (0%)		0 (0%)
Mean (SD)	25.1 (5.37)		24.1 (4.52)		22.7 (3.91)		23.7 (3.99)	
maternal weight gain (kg)		11 (11.0%)		0 (0%)		1 (1.1%)		0 (0%)
Mean (SD)	13.1 (5.89)		14.4 (5.20)		12.4 (4.44)		14.2 (4.82)	
paternal height (cm)		1 (1.0%)		5 (4.6%)		0 (0%)		1 (1.1%)
Mean (SD)	176 (7.21)		179 (7.51)		177 (6.31)		177 (6.48)	
paternal weight (kg)		0 (0%)		5 (4.6%)		0 (0%)		1 (1.1%)
Mean (SD)	85.0 (14.5)		81.2 (10.8)		78.3 (9.65)		81.3 (13.7)	
paternal age (years)		0 (0%)		4 (3.7%)		1 (1.1%)		0 (0%)
Mean (SD)	34.2 (5.04)		31.7 (4.77)		36.8 (5.48)		33.6 (4.06)	
delivery		0 (0%)		0 (0%)		0 (0%)		1 (1.1%)
vaginal	38 (38.0%)		103 (94.5%)		64 (67.4%)		79 (90.8%)	
caesarean	62 (62.0%)		6 (5.5%)		31 (32.6%)		7 (8.0%)	
pregnancy diabetes		0 (0%)		0 (0%)		0 (0%)		33 (37.9%)
no	89 (89.0%)		107 (98.2%)		88 (92.6%)		49 (56.3%)	
yes	11 (11.0%)		7 (7.4%)		11 (11.0%)		2 (1.8%)	
birth weight (g)		0 (0%)		0 (0%)		0 (0%)		0 (0%)
Mean (SD)	3270 (428)		3420 (551)		3230 (406)		3290 (402)	
gestational age (weeks)		0 (0%)		0 (0%)		0 (0%)		0 (0%)
Mean (SD)	38.4 (1.32)		39.0 (1.61)		39.6 (1.60)		39.9 (1.54)	
ethnicity		0 (0%)		0 (0%)		0 (0%)		0 (0%)
non native	5 (5.0%)		18 (16.5%)		8 (8.4%)		4 (4.6%)	
native	95 (95.0%)		89 (81.7%)		87 (91.6%)		83 (95.4%)	
paternal BMI		1 (1.0%)		5 (4.6%)		0 (0%)		1 (1.1%)
Mean (SD)	27.2 (3.90)		25.3 (3.10)		24.9 (2.70)		25.8 (3.63)	
breast feeding		4 (4.0%)		109 (100%)		3 (3.2%)		0 (0%)
no	12 (12.0%)		0 (0%)		12 (12.6%)		7 (8.0%)	
yes	84 (84.0%)		0 (0%)		80 (84.2%)		80 (92.0%)	
breast feeding duration (weeks)		4 (4.0%)		109 (100%)		19 (20.0%)		0 (0%)
Mean (SD)	19.3 (20.7)		NA (NA)		42.5 (28.9)		23.3 (17.4)	
rapid growth		0 (0%)		13 (4.7%)		0 (0%)		0 (0%)
no	60 (60.0%)		76 (69.7%)		82 (83.7%)		62 (71.3%)	
yes	40 (40.0%)		33 (30.3%)		16 (16.3%)		25 (28.7%)	
Vegetables (serves/day)		0 (0%)		0 (0%)		0 (0%)		0 (0%)
Mean (SD)	4.04 (2.87)		1.79 (0.829)		1.13 (0.630)		2.36 (1.17)	
Fruits (serves/day)		0 (0%)		109 (100%)		0 (0%)		0 (0%)
Mean (SD)	2.12 (2.35)		NA (NA)		0.956 (0.441)		2.88 (1.58)	

Milk products (serves/day)		0 (0%)		109 (100%)	0 (0%)		0 (0%)
Mean (SD)	2.42 (1.45)		NA (NA)		1.08 (0.593)		3.08 (1.34)
Fish (serves/day)		0 (0%)		0 (0%)	0 (0%)		0 (0%)
Mean (SD)	0.196 (0.198)		2.21 (1.05)		0.175 (0.101)		0.774 (0.559)
Pulses (serves/day)		0 (0%)		109 (100%)	0 (0%)		0 (0%)
Mean (SD)	0.422 (0.513)		NA (NA)		0.198 (0.195)		0.250 (0.286)
Sugar (serves/day)		0 (0%)		109 (100%)	0 (0%)		0 (0%)
Mean (SD)	1.29 (1.33)		NA (NA)		0.526 (0.378)		4.04 (2.56)
Eggs (serves/day)		0 (0%)		109 (100%)	0 (0%)		0 (0%)
Mean (SD)	0.178 (0.297)		NA (NA)		0.179 (0.132)		0.379 (0.179)
Grains (serves/day)		0 (0%)		109 (100%)	0 (0%)		0 (0%)
Mean (SD)	3.15 (3.45)		NA (NA)		1.17 (0.354)		2.28 (0.974)
Meat (serves/day)		0 (0%)		109 (100%)	0 (0%)		0 (0%)
Mean (SD)	0.477 (0.436)		NA (NA)		1.30 (0.774)		0.882 (0.344)
Processed meat (serves/day)		10 (10.0%)		109 (100%)	0 (0%)		0 (0%)
Mean (SD)	0.340 (0.433)		NA (NA)		0.222 (0.237)		0.359 (0.303)
Potatoes (serves/day)		0 (0%)		109 (100%)	0 (0%)		0 (0%)
Mean (SD)	0.596 (0.612)		NA (NA)		0.228 (0.154)		0.526 (0.317)

Table S2: Individual number, observation number, demographic, anthropometric and clinical outcome variables average values (standard deviation) or percent (%) for overweight throughout early childhood by cohort.

	RHEA (n=97)	Missing	Piccolipiu (n=79)	Missing	INMA (n=96)	Missing
cohort						
RHEA	97 (100%)		-		-	
ENVIRONAGE	-		-		-	
Piccolipiu	-		79 (100%)		-	
INMA	-		-		96 (100%)	
age at weight status assessment		0 (0%)		0 (0%)		0 (0%)
Mean (SD)	5.53 (1.03)		4.43 (0.105)		6.16 (0.635)	
Median [Min, Max]	6.02 [4.01, 7.07]		4.42 [4.17, 4.75]		6.14 [4.04, 7.49]	
gender						
male	53 (54.6%)		44 (55.7%)		48 (50.0%)	
female	44 (45.4%)		35 (44.3%)		48 (50.0%)	
maternal parity before this pregnancy		2 (2.1%)		0 (0%)		1 (1.0%)
nulliparous	26 (26.8%)		37 (46.8%)		51 (53.1%)	
uniparous	46 (47.4%)		37 (46.8%)		37 (38.5%)	
multiparous	23 (23.7%)		5 (6.3%)		7 (7.3%)	
maternal age (years)		0 (0%)		1 (1.3%)		0 (0%)
Mean (SD)	30.2 (4.94)		33.7 (4.61)		31.6 (4.09)	
Median [Min, Max]	29.8 [20.3, 41.7]		33.9 [19.9, 42.8]		31.8 [23.6, 41.3]	
mother's education		1 (1.0%)		0 (0%)		0 (0%)
primary school	7 (7.2%)		4 (5.1%)		18 (18.8%)	
secondary school	55 (56.7%)		33 (41.8%)		44 (45.8%)	
university or higher	34 (35.1%)		42 (53.2%)		34 (35.4%)	
father's education		2 (2.1%)		0 (0%)		1 (1.0%)
primary school	20 (20.6%)		11 (13.9%)		27 (28.1%)	
secondary school	55 (56.7%)		37 (46.8%)		46 (47.9%)	
university or higher	20 (20.6%)		31 (39.2%)		22 (22.9%)	
maternal smoking		1 (1.0%)		0 (0%)		1 (1.0%)
no	77 (79.4%)		65 (82.3%)		74 (77.1%)	
yes	19 (19.6%)		14 (17.7%)		21 (21.9%)	
passive smoke exposure		5 (5.2%)		0 (0%)		2 (2.1%)
no	13 (13.4%)		62 (78.5%)		48 (50.0%)	
yes	79 (81.4%)		17 (21.5%)		46 (47.9%)	
maternal height (cm)		1 (1.0%)		0 (0%)		2 (2.1%)
Mean (SD)	163 (5.56)		164 (6.04)		163 (6.59)	
maternal weight (kg)		1 (1.0%)		0 (0%)		0 (0%)
Mean (SD)	67.1 (15.7)		59.8 (10.6)		62.3 (10.5)	
maternal BMI		1 (1.0%)		0 (0%)		0 (0%)
Mean (SD)	25.2 (5.42)		22.2 (3.67)		23.4 (3.64)	
maternal weight gain (kg)		11 (11.3%)		0 (0%)		0 (0%)
Mean (SD)	13.0 (5.78)		12.3 (4.19)		14.3 (4.97)	
paternal height (cm)		1 (1.0%)		0 (0%)		2 (2.1%)
Mean (SD)	177 (7.14)		178 (6.24)		177 (6.80)	

paternal weight (kg)		0 (0%)		0 (0%)		2 (2.1%)
Mean (SD)	85.1 (14.4)		79.1 (11.1)		81.1 (13.3)	
paternal age (years)		0 (0%)		1 (1.3%)		0 (0%)
Mean (SD)	34.2 (5.02)		36.7 (5.50)		33.5 (4.32)	
delivery		0 (0%)		0 (0%)		1 (1.0%)
vaginal	36 (37.1%)		50 (63.3%)		84 (87.5%)	
caesarean	61 (62.9%)		29 (36.7%)		11 (11.5%)	
pregnancy diabetes		0 (0%)		0 (0%)		41 (42.7%)
no	87 (89.7%)		73 (92.4%)		50 (52.1%)	
yes	10 (10.3%)		6 (7.6%)		5 (5.2%)	
birth weight (g)		0 (0%)		0 (0%)		0 (0%)
Mean (SD)	3270 (428)		3230 (406)		3290 (402)	
gestational age (weeks)		0 (0%)		0 (0%)		0 (0%)
Mean (SD)	38.4 (1.30)		39.7 (1.49)		39.8 (1.51)	
Median [Min, Max]	38.4 [34.2, 41.1]		39.6 [36.6, 44.6]		39.9 [34.3, 44.7]	
ethnicity		0 (0%)		0 (0%)		0 (0%)
native	4 (4.1%)		5 (6.3%)		4 (4.2%)	
non native	93 (95.9%)		74 (93.7%)		92 (95.8%)	
paternal BMI		1 (1.0%)		0 (0%)		2 (2.1%)
Mean (SD)	27.2 (3.82)		24.9 (3.18)		25.8 (3.46)	
breast feeding		4 (4.1%)		1 (1.3%)		0 (0%)
no	12 (12.4%)		10 (12.7%)		8 (8.3%)	
yes	81 (83.5%)		68 (86.1%)		88 (91.7%)	
breast feeding duration (weeks)		4 (4.1%)		16 (20.3%)		0 (0%)
Mean (SD)	18.8 (20.4)		42.9 (28.8)		23.1 (17.4)	
overweight/obesity^a population		0 (0%)		0 (0%)		0 (0%)
no	66 (68.0%)		75 (94.9%)		67 (69.8%)	
yes	31 (32.0%)		4 (5.1%)		29 (30.2%)	
rapid growth		0 (0%)		0 (0%)		12 (12.5%)
no	59 (60.8%)		82 (83.7%)		60 (62.5%)	
yes	38 (39.2%)		16 (16.3%)		24 (25.0%)	
Vegetables (serves/day)		0 (0%)		0 (0%)		1 (1.0%)
Mean (SD)	4.09 (2.88)		1.13 (0.665)		2.31 (1.18)	
Fruits (serves/day)		0 (0%)		0 (0%)		1 (1.0%)
Mean (SD)	2.15 (2.38)		0.951 (0.458)		2.81 (1.54)	
Milk products (serves/day)		0 (0%)		0 (0%)		1 (1.0%)
Mean (SD)	2.42 (1.47)	1.10 (0.574)	1.10 (0.574)		3.12 (1.30)	
Fish (serves/day)		0 (0%)		0 (0%)		1 (1.0%)
Mean (SD)	0.195 (0.200)	0.175 (0.106)	0.175 (0.106)		0.764 (0.551)	
Pulses (serves/day)		0 (0%)		0 (0%)		1 (1.0%)
Mean (SD)	0.427 (0.519)		0.186 (0.157)		0.249 (0.277)	
Sugar (serves/day)		0 (0%)		0 (0%)		1 (1.0%)
Mean (SD)	1.30 (1.34)		0.548 (0.389)		3.97 (2.54)	
Eggs (serves/day)		0 (0%)		0 (0%)		1 (1.0%)
Mean (SD)	0.177 (0.298)		0.175 (0.115)		0.381 (0.173)	
Grains (serves/day)		0 (0%)		0 (0%)		1 (1.0%)
Mean (SD)	3.12 (3.47)		1.18 (0.343)		2.23 (0.958)	
Meat (serves/day)		0 (0%)		0 (0%)		1 (1.0%)
Mean (SD)	0.480 (0.442)		1.28 (0.774)		0.869 (0.336)	
Processed meat (serves/day)		0 (0%)		0 (0%)		1 (1.0%)
Mean (SD)	0.337 (0.438)		0.222 (0.229)		0.344 (0.212)	
Potatoes (serves/day)		0 (0%)		0 (0%)		1 (1.0%)
Mean (SD)	0.597 (0.617)		0.216 (0.143)		0.524 (0.313)	

^aClassification based on WHO sex-adjusted and age-adjusted BMI z-scores

101

102

103

Table S3: All metabolomic features significantly associated (FDR 5%) with rapid growth at in first year of life. In case of more than one feature per compound were detected, the feature with highest intensity is written in bold.

Compound	m/z	Rt(min)	Annotation	Estimate	Std Error	t-score	p-value*
1	385.3487	9.076708	Cholestenone	0.725	0.132	5.492	1.88E-04
1	407.3299	9.073516	Cholestenone	0.642	0.127	5.076	8.66E-04
2	269.1894	5.3084226	Unidentified(U8)	-0.571	0.125	-4.558	6.09E-03
3	289.2157	4.8316393	Unidentified (U6)	-0.563	0.125	-4.502	6.34E-03
4	482.2392	3.6582649	Unidentified (U4)	-0.538	0.127	-4.238	1.77E-02

104

*Model was adjusted for child's sex and age at outcome measurement and ethnicity. We used a random *effects* model by cohort

105
106
107

Table S4: Pre-annotated metabolites in cord blood that have been previously identified in the same dataset associated with birthweight (Robinson et al.; Alfano et al.), or because they have previously been reported to predict rapid growth leading to overweight in childhood trajectory (Isganaitis et al.).

ID	Metabolite name	m/z	retention time (minutes)	Reference
1	Leucine	132.1021	1.4519173	Isganaitis et al., 2015
2	Tryptophan	205.0965	2.4842238	Isganaitis et al., 2015
3	Indolelactic acid	206.0822	3.8289883	Robinson et al., 2018
4	Methoxykynurenic acid	220.5393	3.6709497	Robinson et al., 2018
5	Butyrylcarnitine/Isobutyrylcarnitine (C4:0)	232.1537	1.9274178	Robinson et al., 2018
6	Hexenoylcarnitine (C6:1)	258.1699	2.8306587	Robinson et al., 2018
7	Retinol	269.2278	7.2190323	Robinson et al., 2018
8	Octanoylcarnitine (C8:0)	288.2171	4.4222255	Robinson et al., 2018
9	Sphingosine	300.2905	6.4203	Isganaitis et al., 2015
10	Decenoylcarnitine (C10:1)	314.2321	4.8776007	Robinson et al., 2018
11	Progesterone	315.232	6.3944817	Robinson et al., 2018
12	Decanoylcarnitine (C10:0)	316.2489	5.1387444	Robinson et al., 2018
13	Docosahexaenoic acid	329.2482	7.2322	Robinson et al., 2018
14	Dodecenoylcarnitine (C12:1)	342.2641	5.422301	Robinson et al., 2018
15	Dodecanoylcarnitine (C12:0)	344.2797	5.647444	Robinson et al., 2018
16	Tetradecadienylcarnitine (C14:2)	368.2793	5.631012	Robinson et al., 2018
17	Cholesterol	369.3521	9.60744	Alfano et al., 2019
18	Tetradecenoylcarnitine (C14:1)	370.2955	5.840157	Robinson et al., 2018
19	Tetradecanoylcarnitine (C14:0)	372.3112	6.56033	Robinson et al., 2018
20	Cholestenone	385.3487	9.76708	Alfano et al., 2019
21	Hydroxytetradecenoylcarnitine (C14:1-OH)	386.2899	5.568466	Robinson et al., 2018
22	Hexadecadienylcarnitine (C16:2)	396.31	5.9437513	Robinson et al., 2018
23	Hexadecenoylcarnitine (C16:1)	398.3264	6.1093335	Robinson et al., 2018
24	Hydroxyhexadecadienylcarnitine (C16:1-OH)	412.3045	5.749766	Robinson et al., 2018
25	LysoPC(16:1)	494.325	6.817081	Robinson et al., 2018
26	LysoPC(18:3)	518.3216	6.7819257	Robinson et al., 2018
27	LysoPC(18:1)	522.3555	6.979925	Robinson et al., 2018
28	LysoPC(20:2)	548.3681	7.141414	Robinson et al., 2018
29	LysoPC(20:4)	563.3141	6.8930106	(Alfano et al., 2019; Robinson et al., 2018),
30	LysoPC(22:6)	568.3409	6.88448	Robinson et al., 2018
31	LysoPC(22:5)	570.3551	7.206504	Robinson et al., 2018
32	Diacylglycerol (C34:2)	615.4959	9.762555	Robinson et al., 2018
33	Diacylglycerol (C36:4)	639.4946	9.408274	Robinson et al., 2018
34	Diacylglycerol (C36:3)	641.5112	9.9381895	Robinson et al., 2018
35	PC(30:0)	706.541	8.492703	(Alfano et al., 2019; Robinson et al., 2018),
36	PC(32:0)	734.57	8.960004	Robinson et al., 2018
37	PC(34:2)	758.5747	8.684198	Robinson et al., 2018
38	PlasmalogenPC(36:4) or PC(O-36:5)	766.5815	8.858829	Alfano et al., 2019; Robinson et al., 2018
39	PlasmalogenPC(36:3) or PC(O-36:4)	768.5883	9.189	(Alfano et al., 2019; Robinson et al., 2018),
40	PC(36:4)	782.5722	9.57233	(Alfano et al., 2019; Robinson et al., 2018),
41	PC(36:4) isomer	793.5614	8.628368	Robinson et al., 2018
42	Plasmalogen PC(38:4) or PC(O-38:5)	794.6046	9.77853	(Alfano et al., 2019; Robinson et al., 2018),
43	PC(38:4)	810.6053	9.168946	Robinson et al., 2018

108

109

111 *Table S5: Logistic regression odds ratio per standard deviation (95% CI) for rapid growth at twelve months for*
 112 *Model 1* and 2** for the birthweight related metabolites.*

num	Metabolite	Model 1*			Model 2**		
		Odd ratio (95%CI)	p-value	False discovery rate	Odd ratio (95%CI)	p-value	False discovery rate
1	Butyrylcarnitine/Isobutyrylcarnitine (C4:0)	1.231 (0.982,1.543)	7.09E-02	1.42E-01	1.133 (0.855,1.502)	3.84E-01	5.82E-01
2	Decanoylcarnitine (C10:0)	1.193 (0.945,1.506)	1.37E-01	2.37E-01	1.204 (0.915,1.584)	1.85E-01	3.95E-01
3	Decenoylcarnitine (C10:1)	1.405 (1.106,1.785)	5.39E-03	2.32E-02	1.435 (1.087,1.893)	1.07E-02	1.18E-01
4	Dodecanoylcarnitine (C12:0)	1.140 (0.907,1.432)	2.61E-01	3.96E-01	1.195 (0.912,1.566)	1.96E-01	3.95E-01
5	Dodecenoylcarnitine (C12:1)	1.121 (0.896,1.403)	3.17E-01	4.65E-01	1.151 (0.882,1.502)	3.02E-01	5.10E-01
6	Hexadecadienoylcarnitine (C16:2)	1.247 (0.998,1.557)	5.21E-02	1.15E-01	1.138 (0.874,1.482)	3.36E-01	5.27E-01
7	Hexadecenoylcarnitine (C16:1)	1.068 (0.852,1.338)	5.68E-01	6.75E-01	1.060 (0.807,1.391)	6.75E-01	7.56E-01
8	Hexenoylcarnitine (C6:1)	1.261 (0.984,1.617)	6.73E-02	1.41E-01	1.088 (0.808,1.465)	5.77E-01	7.27E-01
9	Hydroxyhexadecadienoylcarnitine (C16:1-OH)	1.180 (0.950,1.466)	1.35E-01	2.37E-01	1.167 (0.901,1.512)	2.41E-01	4.61E-01
10	Hydroxytetradecenoylcarnitine (C14:1-OH)	1.088 (0.868,1.364)	4.63E-01	6.17E-01	1.071 (0.816,1.405)	6.21E-01	7.39E-01
11	Octanoylcarnitine (C8:0)	1.155 (0.918,1.454)	2.18E-01	3.42E-01	1.073 (0.822,1.400)	6.05E-01	7.39E-01
12	Tetradecadienoylcarnitine (C14:2)	1.325 (1.059,1.658)	1.39E-02	4.37E-02	1.315 (1.013,1.706)	3.97E-02	2.01E-01
13	Tetradecanoylcarnitine (C14:0)	1.034 (0.816,1.311)	7.80E-01	8.37E-01	0.991 (0.745,1.318)	9.50E-01	9.50E-01
14	Tetradecenoylcarnitine (C14:1)	1.058 (0.845,1.324)	6.26E-01	7.25E-01	1.048 (0.804,1.366)	7.28E-01	7.81E-01
15	Leucine	1.045 (0.821,1.329)	7.20E-01	7.92E-01	0.902 (0.678,1.200)	4.79E-01	6.40E-01
16	Tryptophan	0.923 (0.736,1.158)	4.89E-01	6.25E-01	0.947 (0.725,1.236)	6.87E-01	7.56E-01
17	Sphingosine	0.942 (0.718,1.236)	6.65E-01	7.50E-01	0.788 (0.605,1.028)	7.94E-02	2.91E-01
18	Docosahexanoic acid	1.292 (1.005,1.660)	4.58E-02	1.06E-01	1.456 (1.109,1.911)	6.78E-03	9.95E-02
19	Diacylglycerol (C34:2)	1.033 (0.778,1.372)	8.20E-01	8.39E-01	1.135 (0.829,1.554)	4.30E-01	6.10E-01
20	Diacylglycerol (C36:3)	1.084 (0.832,1.413)	5.48E-01	6.70E-01	1.273 (0.961,1.688)	9.30E-02	3.11E-01
21	Diacylglycerol (C36:4)	1.123 (0.880,1.432)	3.51E-01	4.98E-01	1.376 (1.054,1.796)	1.91E-02	1.40E-01
22	LysoPC(16:1)	1.004 (0.803,1.256)	9.69E-01	9.69E-01	0.798 (0.608,1.046)	1.02E-01	3.11E-01
23	LysoPC(18:1)	1.185 (0.946,1.484)	1.40E-01	2.37E-01	0.939 (0.717,1.229)	6.45E-01	7.47E-01
24	LysoPC(18:3)	1.090 (0.871,1.365)	4.53E-01	6.17E-01	0.963 (0.732,1.266)	7.86E-01	8.24E-01
25	LysoPC(20:2)	1.303 (1.012,1.677)	3.97E-02	9.71E-02	1.081 (0.822,1.420)	5.78E-01	7.27E-01
26	LysoPC(20:4)	1.435 (1.106,1.861)	6.52E-03	2.39E-02	1.282 (0.949,1.733)	1.06E-01	3.11E-01
27	LysoPC(22:5)	0.971 (0.759,1.243)	8.16E-01	8.39E-01	0.757 (0.564,1.016)	6.33E-02	2.53E-01
28	LysoPC(22:6)	0.862 (0.682,1.090)	2.14E-01	3.42E-01	0.857 (0.657,1.118)	2.55E-01	4.67E-01
29	PC(30:0)	1.312 (1.046,1.647)	1.89E-02	5.55E-02	0.987 (0.749,1.302)	9.29E-01	9.50E-01
30	PC(32:0)	1.396 (1.112,1.753)	4.06E-03	2.20E-02	1.148 (0.885,1.488)	2.99E-01	5.10E-01
31	PC(34:2)	1.542 (1.222,1.946)	2.62E-04	3.84E-03	1.456 (1.132,1.872)	3.46E-03	7.62E-02
32	PC(36:4)	1.415 (1.125,1.779)	2.99E-03	2.19E-02	1.119 (0.856,1.462)	4.11E-01	6.03E-01
33	PC(36:4) isomer	1.417 (1.114,1.802)	4.49E-03	2.20E-02	1.297 (0.988,1.702)	6.06E-02	2.53E-01
34	PC(38:4)	1.274 (1.019,1.593)	3.33E-02	9.15E-02	1.197 (0.928,1.544)	1.67E-01	3.86E-01
35	Plasmalogen PC(38:4) or PC(O-38:5)	1.379 (1.097,1.732)	5.80E-03	2.32E-02	1.099 (0.846,1.429)	4.80E-01	6.40E-01
36	PlasmalogenPC(36:3) or PC(O-36:4)	1.431 (1.142,1.792)	1.84E-03	1.62E-02	1.218 (0.943,1.572)	1.31E-01	3.19E-01
37	PlasmalogenPC(36:4) or PC(O-36:5)	1.484 (1.180,1.868)	7.52E-04	8.27E-03	1.317 (1.011,1.716)	4.11E-02	2.01E-01
38	Cholestenone	2.064 (1.594,2.673)	3.98E-08	1.75E-06	1.755 (1.236,2.491)	1.66E-03	3.32E-03
39	Cholesterol	1.535 (1.220,1.930)	2.49E-04	3.84E-03	1.229 (0.941,1.606)	1.30E-01	3.19E-01
40	Progesterone	1.402 (1.092,1.800)	7.97E-03	2.70E-02	1.428 (1.051,1.940)	2.26E-02	1.42E-01
41	Indolelactic acid	1.300 (1.013,1.667)	3.89E-02	9.71E-02	1.255 (0.938,1.679)	1.26E-01	3.19E-01
42	Methoxykynurenic acid	1.084 (0.859,1.367)	4.98E-01	6.25E-01	1.150 (0.867,1.524)	3.33E-01	5.27E-01
43	Retinol	0.792 (0.603,1.041)	9.41E-02	1.80E-01	0.820 (0.606,1.109)	1.97E-01	3.95E-01

* Model 1 (adjusted for sex and age of child at outcome measurement, ethnicity and we used a random effects model by cohort)

**Model 2 (Model 1 adjusted for maternal BMI, paternal BMI, gestational age, weight gained during pregnancy, paternal education, passive and active smoking status during pregnancy, parity, and mode of delivery)

Table S6: All metabolomic features significantly associated (FDR 5%) with overweight/obesity at early childhood. In case of more than one feature per compound were detected, the feature with highest intensity is written in bold.

Compound	m/z	Rt(min)	Annotation	Estimate	Std Error	t-value	p-value*
5	129.0025	0.4939376	Unidentified (U1)	-0.661	0.185	-3.571	3.55E-04
5	86.99288	0.4942084	Unidentified (U1)	-0.627	0.179	-3.512	4.44E-04
6	196.9619	0.5246815	Unidentified (U2)	0.832	0.219	3.794	1.48E-04
6	253.9104	0.5244932	Unidentified (U2)	0.762	0.214	3.565	3.64E-04
7	514.878	0.5776492	Unidentified (U3)	-0.698	0.170	-4.115	3.88E-05
7	582.8643	0.5770611	Unidentified (U3)	-0.677	0.165	-4.111	3.94E-05
7	446.8882	0.577687	Unidentified (U3)	-0.676	0.165	-4.100	4.14E-05
7	700.8185	0.5779851	Unidentified (U3)	-0.767	0.189	-4.065	4.81E-05
7	378.9011	0.5771529	Unidentified (U3)	-0.683	0.168	-4.063	4.85E-05
7	726.8223	0.5750447	Unidentified (U3)	-0.720	0.179	-4.032	5.53E-05
7	760.8202	0.5745219	Unidentified (U3)	-0.684	0.170	-4.020	5.82E-05
7	650.8544	0.5757769	Unidentified (U3)	-0.612	0.154	-3.981	6.85E-05
7	692.8324	0.5753962	Unidentified (U3)	-0.723	0.182	-3.973	7.11E-05
7	718.8356	0.5748507	Unidentified (U3)	-0.574	0.147	-3.914	9.09E-05
7	242.9253	0.5751633	Unidentified (U3)	-0.696	0.178	-3.906	9.39E-05
7	312.9127	0.5741116	Unidentified (U3)	-0.714	0.183	-3.903	9.49E-05
7	108.9488	0.5738347	Unidentified (U3)	-0.724	0.187	-3.866	1.11E-04
7	106.9512	0.5741819	Unidentified (U3)	-0.713	0.187	-3.821	1.33E-04
7	310.9139	0.5743221	Unidentified (U3)	-0.689	0.180	-3.819	1.34E-04
7	658.8351	0.5753322	Unidentified (U3)	-0.704	0.185	-3.809	1.40E-04
7	176.937	0.5720361	Unidentified (U3)	-0.716	0.189	-3.796	1.47E-04
7	174.9394	0.5723583	Unidentified (U3)	-0.707	0.187	-3.771	1.62E-04
7	828.8043	0.5720578	Unidentified (U3)	-0.645	0.175	-3.696	2.19E-04
7	870.7891	0.5769692	Unidentified (U3)	-0.710	0.196	-3.629	2.84E-04
7	624.843	0.5741374	Unidentified (U3)	-0.726	0.200	-3.620	2.94E-04
7	598.8356	0.5796612	Unidentified (U3)	-0.705	0.195	-3.620	2.95E-04
7	462.8653	0.5798938	Unidentified (U3)	-0.695	0.194	-3.581	3.42E-04
7	394.8761	0.5797012	Unidentified (U3)	-0.695	0.195	-3.571	3.56E-04
7	530.8525	0.579978	Unidentified (U3)	-0.694	0.195	-3.565	3.63E-04
7	666.8233	0.5794433	Unidentified (U3)	-0.712	0.200	-3.557	3.75E-04
7	258.9015	0.5785645	Unidentified (U3)	-0.682	0.193	-3.530	4.15E-04
7	794.8107	0.5737721	Unidentified (U3)	-0.611	0.173	-3.529	4.16E-04
7	734.812	0.5787313	Unidentified (U3)	-0.696	0.197	-3.527	4.21E-04
7	326.8868	0.5771512	Unidentified (U3)	-0.686	0.196	-3.494	4.76E-04
8	154.0264	0.6849625	Unidentified (U4)	-0.702	0.172	-4.088	4.35E-05
9	169.134	0.6985534	Unidentified (U5)	-0.759	0.206	-3.687	2.27E-04
10	209.1159	6.164805	Unidentified (U7)	-0.671	0.181	-3.705	2.12E-04
13	443.4095	8.544215	Unidentified (U9)	0.893	0.221	4.046	5.21E-05
13	460.4366	8.543666	Unidentified (U9)	1.001	0.262	3.822	1.32E-04
14	72.08108	0.8007007	Valine	-0.611	0.163	-3.748	1.78E-04
14	249.0292	0.8028366	Valine	-0.670	0.181	-3.694	2.21E-04


*Model was adjusted for child's sex and age at outcome measurement and ethnicity. We used a random effects model by cohort

Table S7: Logistic regression odds ratio per standard deviation (95% CI) for overweight/obesity in early childhood for Model 1* and 2** for the birthweight related metabolites.

num	Metabolite	Model 1*			Model 2**		
		Odd ratio (95%CI)	p-value	False discovery rate	Odd ratio (95%CI)	p-value	False discovery rate
1	Butyrylcarnitine/isobutyrylcarnitine (C4:0)	0.777 (0.570,1.058)	1.09E-01	6.43E-01	0.734 (0.498,1.081)	1.17E-01	3.58E-01
2	Decanoylcarnitine (C10:0)	0.912 (0.653,1.274)	5.89E-01	8.36E-01	0.868 (0.581,1.296)	4.88E-01	7.67E-01
3	Decenoylcarnitine (C10:1)	1.193 (0.858,1.659)	2.93E-01	7.70E-01	1.155 (0.769,1.734)	4.88E-01	7.67E-01
4	Dodecanoylcarnitine (C12:0)	0.906 (0.646,1.272)	5.70E-01	8.36E-01	0.834 (0.553,1.258)	3.86E-01	7.04E-01
5	Dodecenoylcarnitine (C12:1)	0.902 (0.658,1.235)	5.20E-01	8.36E-01	0.716 (0.476,1.077)	1.09E-01	3.58E-01
6	Hexadecadienoylcarnitine (C16:2)	0.941 (0.701,1.263)	6.86E-01	8.39E-01	0.928 (0.649,1.326)	6.80E-01	9.07E-01
7	Hexadecenoylcarnitine (C16:1)	0.772 (0.544,1.094)	1.46E-01	6.43E-01	0.627 (0.400,0.984)	4.23E-02	3.12E-01
8	Hexenoylcarnitine (C6:1)	0.764 (0.530,1.102)	1.50E-01	6.43E-01	0.613 (0.382,0.984)	4.26E-02	3.12E-01
9	Hydroxyhexadecadienoylcarnitine (C16:1-OH)	1.033 (0.787,1.356)	8.14E-01	9.01E-01	1.040 (0.746,1.449)	8.18E-01	9.66E-01
10	Hydroxytetradecenoylcarnitine (C14:1-OH)	1.096 (0.801,1.498)	5.68E-01	8.36E-01	1.053 (0.711,1.559)	7.96E-01	9.66E-01
11	Octanoylcarnitine (C8:0)	0.963 (0.695,1.333)	8.19E-01	9.01E-01	0.936 (0.643,1.363)	7.31E-01	9.28E-01
12	Tetradecadienecarnitine (C14:2)	1.004 (0.744,1.355)	9.79E-01	9.79E-01	0.940 (0.653,1.352)	7.39E-01	9.28E-01
13	Tetradecanoylcarnitine (C14:0)	0.880 (0.638,1.214)	4.37E-01	8.36E-01	0.776 (0.531,1.133)	1.88E-01	4.22E-01
14	Tetradecenoylcarnitine (C14:1)	0.907 (0.657,1.251)	5.51E-01	8.36E-01	0.779 (0.523,1.160)	2.19E-01	4.37E-01
15	Leucine	0.658 (0.460,0.941)	2.17E-02	4.78E-01	0.469 (0.293,0.751)	1.61E-03	4.90E-02
16	Tryptophan	0.728 (0.529,1.002)	5.11E-02	6.28E-01	0.720 (0.496,1.045)	8.38E-02	3.58E-01
17	Sphingosine	0.821 (0.552,1.221)	3.29E-01	7.70E-01	0.742 (0.507,1.086)	1.25E-01	3.58E-01
18	Docosahexaenoic acid	0.610 (0.412,0.903)	1.35E-02	4.78E-01	0.619 (0.395,0.970)	3.63E-02	3.12E-01
19	Diacylglycerol (C34:2)	0.835 (0.537,1.300)	4.25E-01	8.36E-01	0.640 (0.372,1.100)	1.07E-01	3.58E-01
20	Diacylglycerol (C36:3)	0.920 (0.618,1.368)	6.79E-01	8.39E-01	0.990 (0.654,1.498)	9.63E-01	9.93E-01
21	Diacylglycerol (C36:4)	1.146 (0.820,1.601)	4.24E-01	8.36E-01	1.182 (0.801,1.742)	4.00E-01	7.04E-01
22	LysoPC(16:1)	1.213 (0.880,1.671)	2.38E-01	7.50E-01	1.154 (0.789,1.688)	4.59E-01	7.67E-01
23	LysoPC(18:1)	1.117 (0.813,1.536)	4.94E-01	8.36E-01	1.118 (0.764,1.636)	5.65E-01	7.94E-01
24	LysoPC(18:3)	1.253 (0.917,1.713)	1.56E-01	6.43E-01	1.263 (0.875,1.821)	2.12E-01	4.37E-01
25	LysoPC(20:2)	1.022 (0.704,1.484)	9.09E-01	9.46E-01	1.126 (0.784,1.618)	5.20E-01	7.88E-01
26	LysoPC(20:4)	0.959 (0.689,1.334)	8.03E-01	9.01E-01	0.752 (0.520,1.088)	1.30E-01	3.58E-01
27	LysoPC(22:5)	1.102 (0.759,1.601)	6.10E-01	8.38E-01	0.957 (0.593,1.545)	8.58E-01	9.68E-01
28	LysoPC(22:6)	0.928 (0.664,1.297)	6.61E-01	8.39E-01	0.993 (0.706,1.399)	9.70E-01	9.93E-01
29	PC(30:0)	0.968 (0.702,1.335)	8.42E-01	9.04E-01	1.043 (0.702,1.551)	8.34E-01	9.66E-01
30	PC(32:0)	1.015 (0.746,1.381)	9.25E-01	9.46E-01	1.115 (0.760,1.637)	5.78E-01	7.94E-01
31	PC(34:2)	1.068 (0.775,1.472)	6.87E-01	8.39E-01	1.271 (0.887,1.821)	1.92E-01	4.22E-01
32	PC(36:4)	0.905 (0.661,1.238)	5.31E-01	8.36E-01	0.981 (0.680,1.414)	9.17E-01	9.84E-01
33	PC(36:4) isomer	0.829 (0.616,1.115)	2.14E-01	7.24E-01	0.750 (0.527,1.067)	1.10E-01	3.58E-01
34	PC(38:4)	0.810 (0.594,1.104)	1.81E-01	6.65E-01	0.717 (0.486,1.057)	9.34E-02	3.58E-01
35	Plasmalogen PC(38:4) or PC(O-38:5)	0.795 (0.576,1.096)	1.61E-01	6.43E-01	0.762 (0.522,1.115)	1.61E-01	4.18E-01
36	PlasmalogenPC(36:3) or PC(O-36:4)	0.855 (0.623,1.173)	3.33E-01	7.70E-01	0.809 (0.556,1.178)	2.69E-01	5.15E-01
37	PlasmalogenPC(36:4) or PC(O-36:5)	0.796 (0.582,1.088)	1.53E-01	6.43E-01	0.764 (0.519,1.125)	1.73E-01	4.22E-01
38	Cholestenone	1.312 (0.942,1.826)	1.08E-01	6.43E-01	1.343 (0.923,1.953)	1.23E-01	3.58E-01
39	Cholesterol	0.919 (0.675,1.250)	5.89E-01	8.36E-01	0.999 (0.691,1.445)	9.97E-01	9.97E-01
40	Progesterone	0.732 (0.531,1.009)	5.71E-02	6.28E-01	0.590 (0.383,0.910)	1.71E-02	2.81E-01
41	Indolelactic acid	0.854 (0.629,1.160)	3.13E-01	7.70E-01	0.657 (0.462,0.934)	1.92E-02	2.81E-01
42	Methoxykynurenic acid	1.185 (0.843,1.667)	3.29E-01	7.70E-01	0.977 (0.656,1.456)	9.10E-01	9.84E-01
43	Retinol	0.866 (0.590,1.271)	4.62E-01	8.36E-01	0.731 (0.488,1.094)	1.27E-01	3.58E-01

* Model 1 (adjusted for child sex and age at outcome measurement, ethnicity and we used a random effects model by cohort),


**Model 2 (Model 1 adjusted for maternal BMI, paternal BMI, gestational age, weight gained during pregnancy, paternal education, passive and active smoking status during pregnancy, parity, and mode of delivery)



129


130 *Figure S1: Directed acyclical graph (DAG) to visualise assumptions regarding covariates, metabolome and*
 131 *outcome. Covariates are coloured gray, metabolome black and outcome white. The examining outcomes are: 1)*
 132 *rapid growth at 1st year of age and 2) overweight/obesity in early childhood.*

133



134

135 *Figure S2: Logistic regression odds ratio per standard deviation (95% CI) for rapid growth for Model 2 (adjusted*
 136 *for child sex and age at outcome measurement, ethnicity and we used a random effects model by cohort*
 137 *adjusted for maternal BMI, paternal BMI, gestational age, weight gained during pregnancy, paternal education,*
 138 *passive and active smoking status during pregnancy, parity, and mode of delivery) stratified by cohort for the 8*
 139 *between the 6 nominal statistically significant birthweight related metabolites and the 4 associated with rapid*
 140 *growth at 12 months. Where * is P < 0.05 and ** is FDR < 0.05. Bars show 95% confidence intervals.*




141

142 *Figure S3: Logistic regression odds ratio per standard deviation (95% CI) for overweight/obesity in early*
 143 *childhood for Model 2 (adjusted for child sex and age at outcome measurement, ethnicity and we used a random*
 144 *effects model by cohort adjusted for maternal BMI, paternal BMI, gestational age, weight gained during*
 145 *pregnancy, paternal education, passive and active smoking status during pregnancy, parity, and mode of*
 146 *delivery) stratified by cohort for the 6 nominal statistically significant birthweight related metabolites and the 8*


147
148

associated with overweight/obesity in early childhood. Where * is $P < 0.05$ and ** is $FDR < 0.05$. Bars show 95% confidence intervals.




149

150 *Figure S4: Logistic regression odds ratio per standard deviation (95% CI) for rapid growth for Model 2 (adjusted*
 151 *for child sex, age at outcome measurement, ethnicity and we used a random effects model by cohort adjusted for*
 152 *maternal BMI, paternal BMI, gestational age, weight gained during pregnancy, paternal education, passive and*
 153 *active smoking status during pregnancy, parity, and mode of delivery) stratified by sex for the 7 nominal*
 154 *statistically significant birthweight related metabolites and the 4 associated with rapid growth at 12 months.*
 155 *Where * is $P < 0.05$ and ** is $FDR < 0.05$. Bars show 95% confidence intervals.*



156


157 *Figure S5: Logistic regression odds ratio per standard deviation (95% CI) for overweight/obesity in early*
 158 *childhood for Model 2 (adjusted for child sex, age at outcome measurement, ethnicity and we used a random*
 159 *effects model by cohort adjusted for maternal BMI, paternal BMI, gestational age, weight gained during*
 160 *pregnancy, paternal education, passive and active smoking status during pregnancy, parity, and mode of*
 161 *delivery) stratified by sex for the 6 nominal statistically significant birthweight related metabolites and the 8*
 162 *associated with overweight/obesity in early childhood. Where * is P < 0.05 and ** is FDR < 0.05. Bars show 95%*
 163 *confidence intervals.*



164


165 *Figure S6: Logistic regression odds ratio per standard deviation (95% CI) for rapid growth at twelve months for*
 166 *Model 1 (adjusted for child sex and age at outcome measurement, ethnicity and we used a random effects model*
 167 *by cohort), Model 2 (Model 1 adjusted for maternal BMI, paternal BMI, gestational age, weight gained during*
 168 *pregnancy, paternal education, passive and active smoking status during pregnancy, parity, and mode of*
 169 *delivery) and Model 3 (Model 2 adjusted for birthweight) for the 7 nominal statistically significant birthweight*
 170 *related metabolites and the 4 associated with rapid growth at twelve months. Where * is $P < 0.05$ and ** is*
 171 *FDR < 0.05. Bars show 95% confidence intervals.*

172




173

174 Figure S7: Logistic regression odds ratio per standard deviation (95% CI) for overweight/obesity in early
 175 childhood for Model 1 (adjusted for child sex and age at outcome measurement, ethnicity and we used a random
 176 effects model by cohort), Model 2 (Model 1 adjusted for maternal BMI, paternal BMI, gestational age, weight
 177 gained during pregnancy, paternal education, passive and active smoking status during pregnancy, parity, and
 178 mode of delivery) and Model 3 (Model 2 adjusted for birthweight) for the 6 nominal statistically significant
 179 birthweight related metabolites and the 8 associated with overweight/obesity in early childhood. Where * is $P <$
 180 0.05 and ** is $FDR < 0.05$. Bars show 95% confidence intervals.



181

182 *Figure S8: Logistic regression odds ratio per standard deviation (95% CI) for rapid growth for Model 2 (adjusted*
 183 *for child sex, age at outcome measurement, ethnicity and we used a random effects model by cohort adjusted for*
 184 *maternal BMI, paternal BMI, gestational age, weight gained during pregnancy, paternal education, passive and*
 185 *active smoking status during pregnancy, parity, and mode of delivery) stratified by Small of Gestational Age*
 186 *(SGA) for the 7 nominal statistically significant birthweight related metabolites and the 4 associated with rapid*
 187 *growth at 12 months. Where * is P < 0.05 and ** is FDR < 0.05. Bars show 95% confidence intervals.*



188

189 *Figure S9: Logistic regression odds ratio per standard deviation (95% CI) for overweight/obesity in early*
 190 *childhood for Model 2 (adjusted for child sex, age at outcome measurement, ethnicity and we used a random*
 191 *effects model by cohort adjusted for maternal BMI, paternal BMI, gestational age, weight gained during*
 192 *pregnancy, paternal education, passive and active smoking status during pregnancy, parity, and mode of*
 193 *delivery) stratified by Small of Gestational Age (SGA) for the 6 nominal statistically significant birthweight related*
 194 *metabolites and the 8 associated with overweight/obesity in early childhood. Where * is $P < 0.05$ and ** is*
 195 *FDR < 0.05. Bars show 95% confidence intervals.*

196

197
198
199

1. Study population

200 The ENVIRONAGE cohort recruits since 2010, and the sampling of this specific study
201 population occurred between 2014 and 2015 in Belgium. Women were recruited when they
202 arrived at the South-East-Limburg Hospital in Gent. Follow-up anthropometric data collection
203 for children is available up to two years of age. ENVIRONAGE study was approved by the
204 ethical committees of Hasselt University and Hospital East-Limburg, Genk, Belgium. The
205 INMA cohort is a network of birth cohorts in Spain that recruited pregnant women from the
206 first trimester at public primary health care centers or hospitals in Sabadell from July 2004 to
207 July 2006. Follow-up anthropometric data measurements, samples and surveys of the
208 participating children have been collected until 16 years of age. INMA study was approved
209 by the Ethical Committee of the Municipal Institute of Medical Investigation. The Piccolipiu
210 study recruited women giving birth between 2011 and 2013 at selected hospitals in five
211 Italian cities, Turin, Trieste, Viareggio, Florence, Rome. Children included in STOP were
212 selected from the Turin center. Follow-up anthropometric data collection surveys occurred at
213 6, 12 and 24 months after the delivery and then when the children turned 4 and 6 years with
214 direct measurements at a clinical visit. For Piccolipiu study, Ethical approvals have been
215 obtained from the Ethics Committees of the Local Health Unit Roma E (management
216 center), of the Istituto Superiore di Sanità (National Institute of Public Health), and of each
217 local center. The Rhea cohort enrolled women during the first trimester of pregnancy at
218 public primary health care centres or hospitals in Heraklion, Greece, between 2007 and
219 2008. Follow-up anthropometric measurements, samples and surveys for the participants
220 are available up to 11 years. Follow-up anthropometric measurements, samples and surveys
221 for the participants are available up to 11 years. Rhea was approved by the ethical
222 committee of the University Hospital in Heraklion, Crete, Greece. For all studies, informed
223 consent was given by all participants.

224 Venipuncture was used for collecting blood samples of cord vessels before the placenta was
225 delivered. Samples were processed into either plasma (Environage, Piccolipiu) or serum
226 (Rhea, INMA) as previously described¹. Cohort inclusion criteria and further protocols can be
227 found in the respective cohort references. Samples were selected from each cohort on the
228 basis of biomaterial and data availability²⁻⁵. Selected samples were shipped to the
229 International Agency for Research on Cancer, Lyon, France for metabolomics analysis.

230 Family lifestyle factors were collected from mothers through an interview by trained
231 fieldworkers and medical history for each family transferred from hospital records¹.

232 Regarding maternal diet during pregnancy (Table S1-S2), in the INMA cohort, an adapted
233 version of Willett's questionnaire⁶ was developed and validated for the Spanish
234 population⁷. A Food Frequency Questionnaire (FFQ) was administered by trained
235 interviewers during the 3rd trimester. The questionnaire consisted of question related to the
236 frequency that a participant had consumed specific types of food⁸. The questionnaire had
237 nine possible intake food categories, ranging from 'never or less than once per month' to '6
238 or more times per day'. The average daily food consumption calculated based on the overall
239 intake frequency for each food item intake for each participant. In the RHEA cohort was
240 developed a semi-quantitative questionnaire, containing 250 food items⁸. The participants
241 were asked about both the frequency of consumption and the average portion size. The
242 exact frequency of consumption was given per day, per week and/or per month, depending
243 on the food item. The intake frequency for each food item was converted to the average
244 daily intake for each participant. In the ENVIRONAGE cohort information on the maternal
245 diet during the pregnancy was derived from the questionnaire filled out after delivery,
246 including questions on the consumption of soft drinks, fish, fruit, and vegetable intake.
247 Participants were asked for the frequency of average portion consumption per day and/or
248 per week, depending on the food item. In the Piccolipiu cohort an FFQ for 13 items based on
249 other questionnaires, but not ad hoc validated, was used.

250 2. Untargeted metabolomics

251 Cord blood samples were prepared by protein precipitation and analyzed in randomized
252 order as a single uninterrupted batch with a UHPLC-QTOF-MS system consisting of a 1290
253 Binary LC, a Jet Stream electrospray ionization source, and a 6550 QTOF mass
254 spectrometer (Agilent Technologies). Details of the analysis have been described earlier
255 Robinson, Keski-Rahkonen *et al*¹. In short, 30 μ L of the sample was mixed with 200 μ L of
256 acetonitrile and filtered with 0.2 μ m polypropene well plate filters, and the analysis was
257 performed on a reversed phase column using a 13-minute methanol-water gradient. The
258 mass spectrometer was operated in positive polarity with a mass range of 50-1000 Da.
259 Preprocessing of the acquired data was carried out using Agilent's recursive feature finding
260 workflow as described earlier in detail¹. Briefly, a molecular feature extraction algorithm was
261 used to find singly charged proton adducts, which were filtered by detection frequency and
262 peak size into a target list of features, which were extracted from the raw data using a find-
263 by-ion algorithm with a matching tolerance for the mass and retention time at \pm 10 ppm and
264 \pm 0.04 min. Peak areas were used as a measurement of feature intensity. Metabolic features
265 present in <60% of the samples were removed and data were log-transformed. Missing
266 values were imputed leaving 4714 features for analysis using imputeLCMD R package⁹. For
267 identification of the features discovered in the present study, mass-to-charge ratios (m/z)
268 were searched in the Human Metabolome Database¹⁰ and METLIN¹¹, using ions [M+H]⁺,
269 [M-H₂O+H]⁺ and [M+Na]⁺, with 15 ppm molecular weight tolerance. Identity of the candidate
270 metabolites was confirmed by reanalysis of representative samples together with pure
271 chemical standards and comparing retention times and MS/MS spectra. When standards
272 were not available, MS/MS spectra were acquired when possible and compared against
273 those in public databases (www.mzcloud.org, METLIN). Level of identification was defined
274 as proposed by Sumner, Amberg *et al*¹². Chromatograms and mass spectra of all identified
275 compounds are provided in the Supporting Information.

276 **3. Random Forest and model evaluation for optimism**

277 A bootstrap method of 1000 repetitions was advocated to quantify optimism and evaluate the
278 generalization of the model. In this analysis, we had two dependent variables to examine.
279 The first dependent variable was the rapid growth at twelve months of age and the second in
280 early childhood as it was defined in the main text. We used three different sets of
281 independent variables for each of the outcomes: 1) traditional risk factors (cohort, ethnicity,
282 maternal BMI, paternal BMI, gestational age, maternal weight gained during pregnancy,
283 paternal education, maternal passive and active smoking status during pregnancy, parity
284 and mode of delivery), 2) significantly associated metabolites from the MWAS analysis, and
285 3) significantly associated metabolites in combination with traditional risk factors. All the
286 models were adjusted for age and gender. A Random Forest classification model of 250
287 trees was trained on the relevant training set using Scikit-learn default parameters¹³.

288 For all the bootstrapped models, we use a training set (random 80% of the total
289 observations) to determine the optimum probability threshold, and the performance was
290 evaluated on the relevant test set (remaining 20% of the total observations) for the cohorts
291 that remained to the sample. The performance of all the models was assessed through
292 receiver operating characteristic (ROC curve), and we estimate the bootstrapped 95%
293 confidence intervals.

294 To further evaluate the predictive model, we performed a leave-one-out analysis by

295 repeating the modelling process on a combined data set with one cohort out. We carried out
296 this evaluation step following the above-mentioned methodology.

297 The results showed that the rapid growth prediction model trained using only traditional risk
298 factors and exhibited a moderate predictive ability of an AUROC value of 0.69 (bootstrap

299 95% confidence interval (CI): 0.62, 0.77)). Adding the four metabolites (cholestenone, U2,
 300 U4, and U8) identified in the MWAS analysis into the prediction model, increased the
 301 AUROC to 0.77 (bootstrap 95% confidence interval (CI): 0.71, 0.83)) (Table S8). For
 302 overweight, using traditional risk factors alone, the AUROC was 0.69 (bootstrap 95%
 303 confidence interval (CI): 0.63, 0.75)), while a model using only the eight metabolites, Valine,
 304 U1, U2, U3, U4, U5, U7 and U9, identified in the MWAS analysis had an AUROC of 0.76
 305 (bootstrap 95% confidence interval (CI): 0.69, 0.81)). The combined traditional risk factor
 306 and metabolite model was strongly predictive of overweight with an AUROC of 0.82
 307 (bootstrap 95% confidence interval (CI): 0.79, 0.85)) (Table S8).

308 *Table S8: Summary of rapid growth and 12 months of age and overweight/obesity in childhood. Average AUROC*
 309 *across 1000 bootstrapped test sets for all the cohorts.*

Model*		Rapid growth at 12 months of age			Overweight/obesity in early childhood		
		Average AUROC	Lower 95%CI	Upper 95%CI	Average AUROC	Lower 95%CI	Upper 95%CI
1	Questionnaires**	0.69	0.62	0.77	0.69	0.63	0.75
2	Metabolomics***	0.72	0.64	0.81	0.76	0.69	0.81
3	Metabolomics and questionnaires****	0.77	0.71	0.83	0.82	0.79	0.85

*All the models were adjusted for age and sex.

**Multivariate analysis for cohort, ethnicity, maternal BMI, paternal BMI, gestational age, maternal weight gained during pregnancy, paternal education, maternal passive and active smoking status during pregnancy, parity, and mode of delivery.

Multivariate analysis of rapid growth at 12 months of age for Cholestenone, U4, U6 and U8 and of overweight/obesity in early childhood for Valine, U1, U2, U3, U4, U5, U7 and U9* Multivariate model using the covariates of model 1 and 2.

310
311
312
313
314
315

316 *Table S9: Summary of rapid growth and 12 months of age and overweight/obesity in childhood. Average ROC*
 317 *and CI95% across 1000 bootstrapped test sets using and leave-cohort-out approach.*

Model*		Validation cohort	Rapid growth at 12 months of age			Overweight/obesity in early childhood		
			Average AUROC	Lower 95%CI	Upper 95%CI	Average AUROC	Lower 95%CI	Upper 95%CI
1	Questionnaires**	ENVIRONAGE	0.72	0.68	0.74	-	-	-
		Piccolipiu	0.74	0.69	0.79	0.79	0.75	0.83
		RHEA	0.61	0.57	0.66	0.63	0.61	0.65
		INMA-Sabadell	0.80	0.77	0.83	0.68	0.64	0.72
2	Metabolomics***	ENVIRONAGE	0.64	0.61	0.67	-	-	-
		Piccolipiu	0.68	0.64	0.72	0.62	0.59	0.73
		RHEA	0.74	0.73	0.75	0.75	0.71	0.78
		INMA-Sabadell	0.70	0.67	0.73	0.62	0.58	0.64
3	Metabolomics and questionnaires****	ENVIRONAGE	0.70	0.67	0.74	-	-	-
		Piccolipiu	0.81	0.76	0.83	0.64	0.60	0.68
		RHEA	0.65	0.61	0.68	0.79	0.74	0.83

	INMA-Sabadell	0.82	0.79	0.85	0.71	0.68	0.74
--	---------------	------	------	------	------	------	------


318
319
320
321
322
323

*All the models were adjusted for age and sex.
 **Multivariate analysis for ethnicity, maternal BMI, paternal BM, gestational age, maternal weight gained during pregnancy, paternal education, maternal passive and active smoking status during pregnancy, parity, and mode of delivery.
 ***Multivariate analysis of rapid growth at 12 months of age for Cholestenone, U4, U6 and U8 and of overweight/obesity in early childhood for Valine, U1, U2, U3, U4, U5, U7 and U9
 ****Multivariate model using the covariates of model 1 and 2.

324
325
326
327
328
329
330
331
332
333

The results of the leave one cohort out analysis (Table S9) for rapid growth showed an improvement in predictive performance upon addition of metabolites for Piccolipiu, Rhea and INMA as validation cohorts. For overweight, the leave one cohort out analysis (Table S9) showed an improvement in predictive performance upon addition of metabolites for Rhea and INMA as validation cohorts. These differences in predictive performance across cohorts may reflect the heterogeneity of the metabolic profiles we observed in each cohort and also, for overweight models, the lower age range and proportion of overweight cases in the Piccolipiu cohort (Figure S10).

The statistical analyses were performed using R ('The R Project for Statistical Computing') software environment (v3.5.2) and Python 3.6.



334
335
336
337

Figure S10: PCA analysis of the whole metabolome and scatter plot of first two principal components, coloured by cohort.

338
339

340 **4. Metabolic pathway enrichment analysis**

341 We performed pathway enrichment analysis using Mummichog (version: 2.3.3-20200213,
342 default metabolic human model MFN_1.10.4.). Mummichog is a bioinformatics Python-based
343 platform that infers and categorizes functional biological activity using directly the output
344 from mass spectrometry¹⁴. The algorithm searches tentative compound lists from metabolite
345 reference databases against an integrated model of human metabolism to identify functional
346 activity. Fisher's exact tests are used to infer p-values, which are adjusted for type I error
347 through a pathway permutation procedure. Likelihood of pathway enrichment across
348 significant features is compared to pathways identified across the entire compound set in a
349 reference list (the entire metabolome dataset), considering the probability of mapping the
350 significant metabolic features to pathways. Mummichog parameters were set to match
351 against ions included in the 'positive mode' setting at ± 8 ppm mass tolerance ("M+H[1+]" and
352 "M+Na[1+]").

353 Mummichog assigned tentative annotations to 405 of the 4714 features as significant
354 ($P < 0.05$) for rapid growth in 12 months (Supporting information 2) and to 613 of the 4714 for
355 overweight/obesity in early childhood (Supporting information 3). Mummichog reference
356 feature list was mapped to 627 Empirical Compounds which 69 were statistically significant
357 for rapid growth in 12 months and 78 statistically significant for overweight/obesity in early
358 childhood. According Mummichog, Empirical Compounds are putative metabolites as
359 measured by Liquid chromatography coupled to high-resolution mass spectrometry (LC-
360 HRMS). These putative metabolites can contain a mixture of enantiomers, stereoisomers,
361 and positional isomers that are not resolved by the instruments¹⁵.

362 The results showed that the three enriched pathways with overlap size ≥ 4 for rapid growth in
363 infancy were "Androgen and estrogen biosynthesis and metabolism", "C21-steroid hormone
364 biosynthesis and metabolism" and "Urea cycle/amino group metabolism" (Table S10) and

365 enriched pathways with overlap size ≥ 4 for overweight/obesity in early childhood were
 366 “Valine, leucine and isoleucine degradation”, “Biopterin metabolism” and “Glycine, serine,
 367 alanine and threonine metabolism”(Table S11).

368 Additionally, to further validate the pathways proposed by mummichog, we carried out a
 369 manual curation of the metabolite identities assigned by mummichog. For the compounds
 370 previously identified by the laboratory and for which pure chemical standards were available,
 371 retention times were compared to exclude false mummichog annotations.

372 The results of this manual validation lend support for the correctness of following
 373 mummichog-predicted pathways: for rapid growth, “C21-steroid hormone biosynthesis and
 374 metabolism”, “androgen and estrogen biosynthesis and metabolism”, and “Urea cycle/amino
 375 group metabolism” retained overlap sizes of 13,12 and 5, respectively after excluding the
 376 false metabolite annotations (Table S10). For overweight, “Glycine, serine, alanine and
 377 threonine metabolism” retained an overlap size of 5, although the statistical support was
 378 weak ($p = 0.05$ before manual exclusion) (Table S11).

379 *Table S10: Mummichog analysis statistically significant pathways for rapid growth at 12 months of age.*

Pathways	Overlap size ^A	Pathway size ^B	p-value ^C	Overlap empirical compounds ^E
C21-steroid hormone biosynthesis and metabolism	15	58	8e-05	E285, E479, E151 ^D , E423, E487 ^D , E124, E181, E309, E386, E539, E219, E382, E379, E416, E36
Androgen and estrogen biosynthesis and metabolism	12	30	8e-05	E285, E386, E36, E423, E124, E416, E309, E219, E539, E463, E209, E382
Urea cycle/amino group metabolism	8	34	0.007	E288 ^D , E387, E94, E57 ^D , E488 ^D , E98, E548 ^D , E37 ^D

A Pathway size is number of detected Empirical Compounds for each pathway.

B Overlap size is number of significant Empirical Compounds.

C Empirical p-values are estimated by permutation test.

D This empirical compound has not been identified in the manual identification.

380
 381
 382
 383

384 E Details on empirical compounds are available in supporting information 2.
385

386 *Table S11: Mummichog analysis statistically significant pathways for overweight/obesity in early childhood.*

Pathways	Overlap size ^A	Pathway size ^B	p-value ^C	Overlap empirical compounds ^E
Valine, leucine and isoleucine degradation	6	13	0.0006	E34, E17, E239, E350 ^D , E549 ^D , E180 ^D
Biopterin metabolism	4	9	0.005	E484 ^D , E601, E290 ^D , E175
Glycine, serine, alanine and threonine metabolism	8	42	0.050	E17, E350 ^D , E449, E3, E407, E549 ^D , E180 ^D , E394

387 A Pathway size is number of detected Empirical Compounds for each pathway.
388 B Overlap size is number of significant Empirical Compounds.
389 C Empirical p-values are estimated by permutation test.
390 D This empirical compound has not been identified in the manual identification.
391 E Details on empirical compounds are available in supporting information 3.

392 5. Modelling of weight and height growth trajectories

393 Patterns of growth across childhood follow a complex pattern (growth is non-linear). We
394 used a two-step approach to estimate growth curves for participating cohorts. First, we
395 identified for each cohort the best fitting fractional polynomials of age and constructed sex-
396 and age- specific weight and height growth curves¹⁶. Briefly, a series of models were carried
397 out for each cohort in which age was raised to a large number of combinations of powers
398 (each of the following single powers, plus each combination of two powers: -2, -1, -0.5, 0,
399 0.5, 1, 2, 3, where a power of zero is the log function), resulting in a wide range of possible
400 weight and height curves¹⁷. Then we used mixed-effects linear regression models with the
401 previously identified fractional polynomials of age, including a random intercept for child and
402 random age slopes. Such models allow for individual variation in growth curves within each
403 cohort, and use all available data from all the eligible children under a missing at random
404 assumption¹⁸. Predicted weight and height values within each cohort were estimated for the
405 exact age of 12months for the cohorts' individuals.

406 We used the WHO growth charts to monitor child growth^{19, 20}. These charts are growth
407 standards based on data collected from selected communities worldwide. The use of WHO
408 standards allows for growth assessment of children independent of ethnicity and
409 socioeconomic status, thus, permitting international comparisons. These charts have been


410 adopted in a growing number of countries in Europe and other parts of the world ²¹, and
 411 endorsed by international bodies such as the United Nations Standing Committee on
 412 Nutrition ²² and International Pediatric Association ²³.

413 The selected models are available in Table S12 and the performance of the models are
 414 presented in Figure S11-S14.

415 *Table S12: Comparison of prediction concordance from different fractional polynomial powers for sex-specific*
 416 *weight and height in participating cohorts.*


Cohort	N	n	Boys										Girls									
			Weight					Height					Weight				Height					
			Powers	rho _c *	Difference		Powers	rho _c *	Difference		Powers	rho _c *	Difference		Powers	rho _c *	Difference					
					Mean	(SD)			Mean	(SD)			Mean	(SD)			Mean	(SD)				
ENVIRONAGE	108	1104	-2	0.5	0.994	-0.001	(0.477)	-2	0.5	0.998	-0.011	(1.134)	0	0	0.996	-0.001	(0.408)	-1	0.5	0.998	-0.006	(1.048)
INMA-Sabadell	404	3149	0.5	3	0.997	-0.000	(0.592)	0	1	0.998	-0.000	(1.415)	0.5	3	0.997	0.000	(0.506)	0.5	3	0.998	-0.000	(1.417)
PICCOLIPIU	99	943	0	0	0.991	-0.000	(0.359)	0	0	0.989	-0.000	(1.537)	0.5	1	0.992	0.000	(0.300)	0	0	0.989	-0.000	(1.456)
RHEA	1092	21045	0	0.5	0.989	-0.000	(0.858)	0.5	0.5	0.997	0.000	(1.530)	0.5	3	0.996	-0.000	(0.502)	0.5	1	0.997	0.000	(1.384)

417 * rho_c: concordance correlation coefficient.




418

419 *Figure S11: Actual vs Predicted values of weight and height in participating ENVIRONAGE cohort.*




420

421 *Figure S12: Actual vs Predicted values of weight and height in participating INMA cohort.*



422

423 *Figure S13: Actual vs Predicted values of weight and height in participating Piccolipiu cohort.*



424

425 *Figure S14: Actual vs Predicted values of weight and height in participating RHEA cohort.*

426
427

428 **References**

429 1. Robinson O, Keski-Rahkonen P, Chatzi L, Kogevas M, Nawrot T, Pizzi C *et al.* Cord blood
 430 metabolic signatures of birth weight: a population-based study. *Journal of proteome*
 431 *research* 2018; **17**(3): 1235-1247.

432
 433 2. Chatzi L, Leventakou V, Vafeiadi M, Koutra K, Roumeliotaki T, Chalkiadaki G *et al.* Cohort
 434 profile: the mother-child cohort in Crete, Greece (Rhea study). 2017; **46**(5): 1392-1393k.

435
 436 3. Janssen BG, Madhloum N, Gyselaers W, Bijmens E, Clemente DB, Cox B *et al.* Cohort profile:
 437 the ENVIRONMENTAL influence ON early AGEing (ENVIR ON AGE): a birth cohort study. 2017;
 438 **46**(5): 1386-1387m.

439
 440 4. Farchi S, Forastiere F, Vecchi Brumatti L, Alviti S, Arnofi A, Bernardini T *et al.* Piccolipiù, a
 441 multicenter birth cohort in Italy: protocol of the study. *BMC pediatrics* 2014; **14**: 36-36.

442
 443 5. Guxens M, Ballester F, Espada M, Fernández MF, Grimalt JO, Ibarluzea J *et al.* Cohort profile:
 444 the INMA—Infancia y Medio Ambiente—(environment and childhood) project. *International*
 445 *journal of epidemiology* 2011; **41**(4): 930-940.

446

- 447 6. Willett WC, Sampson L, Stampfer MJ, Rosner B, Bain C, Witschi J *et al.* Reproducibility and
448 validity of a semiquantitative food frequency questionnaire. *American journal of*
449 *epidemiology* 1985; **122**(1): 51-65.
- 450
451 7. Vioque J, Weinbrenner T, Asensio L, Castelló A, Young IS, Fletcher A. Plasma concentrations
452 of carotenoids and vitamin C are better correlated with dietary intake in normal weight than
453 overweight and obese elderly subjects. *British journal of nutrition* 2007; **97**(5): 977-986.
- 454
455 8. Chatzi L, Mendez M, Garcia R, Roumeliotaki T, Ibarluzea J, Tardón A *et al.* Mediterranean
456 diet adherence during pregnancy and fetal growth: INMA (Spain) and RHEA (Greece)
457 mother–child cohort studies. *British Journal of Nutrition* 2012; **107**(1): 135-145.
- 458
459 9. Lazar C. imputeLCMD: a collection of methods for left-censored missing data imputation. *R*
460 *package, version 2015*; **2**.
- 461
462 10. Wishart DS, Feunang YD, Marcu A, Guo AC, Liang K, Vázquez-Fresno R *et al.* HMDB 4.0: the
463 human metabolome database for 2018. *Nucleic Acids Res* 2018; **46**(D1): D608-d617.
- 464
465 11. Smith CA, O'Maille G, Want EJ, Qin C, Trauger SA, Brandon TR *et al.* METLIN: a metabolite
466 mass spectral database. *The Drug Monit* 2005; **27**(6): 747-51.
- 467
468 12. Sumner LW, Amberg A, Barrett D, Beale MH, Beger R, Daykin CA *et al.* Proposed minimum
469 reporting standards for chemical analysis Chemical Analysis Working Group (CAWG)
470 Metabolomics Standards Initiative (MSI). *Metabolomics* 2007; **3**(3): 211-221.
- 471
472 13. Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O *et al.* Scikit-learn:
473 Machine learning in Python. *Journal of machine learning research* 2011; **12**(Oct): 2825-2830.
- 474
475 14. Li S, Park Y, Duraisingham S, Strobel FH, Khan N, Soltow QA *et al.* Predicting network activity
476 from high throughput metabolomics. *PLoS computational biology* 2013; **9**(7): e1003123.
- 477
478 15. Pang Z, Chong J, Li S, Xia J. MetaboAnalystR 3.0: Toward an optimized workflow for global
479 metabolomics. *Metabolites* 2020; **10**(5): 186.
- 480
481 16. Royston P, Wright EM. A method for estimating age-specific reference intervals ('normal
482 ranges') based on fractional polynomials and exponential transformation. *Journal of the*
483 *Royal Statistical Society: Series A (Statistics in Society)* 1998; **161**(1): 79-101.
- 484
485 17. Long J, Ryou J. Using fractional polynomials to model non-linear trends in longitudinal data.
486 *British Journal of Mathematical and Statistical Psychology* 2010; **63**(1): 177-203.
- 487
488 18. Johnson W, Balakrishna N, Griffiths PL. Modeling physical growth using mixed effects
489 models. *American journal of physical anthropology* 2013; **150**(1): 58-67.

490

- 491 19. WHO Multicentre Growth Reference Study Group. *WHO Child Growth Standards:*
492 *Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass*
493 *index-for-age: Methods and development.*, World Health Organization: Geneva, 2006.
- 494
495 20. de Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J. Development of a WHO
496 growth reference for school-aged children and adolescents. *Bull World Health Organ* 2007;
497 **85**(9): 660-7.
- 498
499 21. Turck D, Michaelsen KF, Shamir R, Braegger C, Campoy C, Colomb V *et al.* World Health
500 Organization 2006 child growth standards and 2007 growth reference charts: A discussion
501 paper by the committee on Nutrition of the European Society for Pediatric
502 Gastroenterology, Hepatology, and Nutrition. *J. Pediatr. Gastroenterol. Nutr.* 2013; **57**(2):
503 258-64.
- 504
505 22. UN Standing Committee on Nutrition. UN Standing Committee on Nutrition (SCN) Endorses
506 the New WHO Growth Standards for Infants and Young Children. . In.
- 507
508 23. International Pediatric Association Endorsement. International Pediatric Association
509 Endorsement. The New WHO Growth Standards for Infants and Young Children. In.
- 510
511
512